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CHARACTERIZATION OF MICROREACTOR AND ANALYSIS OF CARBONYL 
COMPOUNDS IN EXHALED BREATH  
Qi Li 
November 19, 2018 
Analysis of trace volatile organic compounds at parts per billion (ppbv) to parts per 
trillion (pptv) level has become an important research frontier because of the applicability 
for environmental monitoring and noninvasive diagnosis of diseases. The methods of 
preconcentration for detection of trace aldehydes and ketones both in ambient air and 
human exhaled breath have increased considerably over the last decade. However, the 
majority of these methods are not efficient. 
In this dissertation, we have improved an innovative microreactor that is suitable 
for quantitative analysis of volatile carbonyl compounds (VOCs) in ambient air as well as 
in human exhaled breath. The approach is based on microreactor chips fabricated from four 
inch silicon wafers. The chips have thousands of micropillars in the microfluidic channels 
for uniformly distributing gaseous samples flowing through the microreactors. The 
surfaces of the micropillars are functionalized with a quaternary ammonium aminooxy salt 
2-(aminooxy)-N,N,N-trimethylethanammonium (ATM) iodide  for trapping trace ketones 
and aldehydes by means of oximation reactions. ATM adducts and unreacted ATM are
vi 
 
eluted from the microreactor with methanol and directly analyzed by UHPLC-MS. 
Design and characterization of the microreactors were first investigated.  The 
reaction kinetics of the aminooxy reagent ATM with carbonyl were obtained. A reactor 
model was established to predicate the relationship between the capture efficiencies of 
carbonyl compounds and the microreactor length at a given gaseous sample flow rate. The 
microreactors were then used to study the stability of breath VOCs. VOCs, collected in 
Tedlar bags, were stable for about two hours with less than 5% of a concentration decrease. 
Storage of breath samples in a refrigerator reduces the concentration changes of VOCs.  
The analysis of exhaled breath samples of patients for early lung cancer screening program 
using the microreactor indicates that C3H6O, C2H4O2 and C4H8O2 can serve as biomarkers 
to distinguish patients with pulmonary nodules from healthy controls. The analysis of 
exhaled breath samples of the lung cancer (LC) patients, patients with benign pulmonary 
nodules and healthy controls led to three VOCs (2-butanone, 3-hydroxy-2-butanone and 4-
hydroxy-2-nonenal (4-HNE)) as markers for distinguishing LC patients from patients with 
benign pulmonary nodules and healthy controls. 4-HNE can also be used to distinguish 
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1. Breath Analysis 
Breath analysis is probably one of the oldest forms of disease diagnosis. Its usage for 
disease diagnostics dates back to ancient Greeks where physicians used exhaled breath to 
diagnose different diseases. 1,2 They already knew that the aroma of human exhaled breath 
could provide clues to disease. Certain diseases have correct associations with breath. For 
example, the fishy smell of breath associates to liver illness, a urine-like smell can accompany 
failing kidneys, the diabetic patients often breathe a sweet smell due to the presence of acetone 
in their breath, the grapes flavor of Pseudomonas infections, 3,4 or the sewer smell of the breath 
of patients with lung abscesses, caused by the proliferation of anaerobic bacteria. 5-7  
Both qualitative and quantitative methods for determination of chemical substances 
in breath are included in breath analysis. In the 1970s, Linus Pauling detected (though 
without identifying) around 200 different volatile organic compounds (VOCs) in exhaled 
breath by gas chromatography. It was demonstrated that normal human breath is a gas 
mixture with rather complex composition. In the last 30 years, researchers identified many
2 
 
of these compounds. It has turned out that exhaled breath contains many VOCs, such as 
acetone, methanol or isoprene and even small inorganic molecules like nitric oxide, carbon 
monoxide or carbonyl sulfide. 8,9     
Breath analysis provides a simple and convenient alternative to traditional medical 
diagnostics in clinical laboratory, because it is non-invasive, painless, cost-effective and it 
can be easily repeated. As we breathe out from our mouth, thousands of molecules are 
expelled into the air. The composition of breath samples is often identified as a mixture of 
volatile organic compounds (VOCs) (e.g., acetone, isoprene, ethane and pentane), simple 
gases (e.g., NO, CO2, and CO), and even some non-volatile substances (e.g., isoprostanes, 
peroxynitrite, cytokines).10 In addition to oxygen, nitrogen, carbon dioxide and water vapor, 
human breath contains hundreds of volatile organic compounds (VOCs) whose 
concentration variations may serve as biomarkers for specific diseases. It is recently proved 
that there are approximately 3000 VOCs have been detected at least once in human breath, 
and most breath samples usually contain more than 200 VOCs. Detailed analysis of their 
composition can provide a diverse signature of physiological processes that took place in 
the body (i.e. breath print) and along the pathways of ingestion or absorption since these 
molecules have been produced from both endogenous and exogenous origins.5 If we can  
capture and analyze this “breath print” correctly, it can be used to provide information of 
the current health status with the potential to predict future outcomes. 11 In that sense, the 
development of efficient devices that can be practically used for the analysis and 




The potential advantages of breath analysis over other conventional medical tests 
include that it is a totally non-invasive and painless method to assess a person’s health state, 
the sampling method of breath analysis is very easy to operate as it does not need skilled 
staff to operate and it can be used to people of all ages and conditions. In recent years, 
breath analysis attracts a lot of attention due to the great potential in clinical diagnostics 
and exposure assessment. 12  
Biomarkers are quantifiable indications of physiologic function and disease activity 
that provide a practical basis for diagnosis and monitoring of pathologic states. 13 In the 
past years, researchers found some compounds can be used to define a disease in person. 
For example, Corradi et al. found that malondialdehyde (MDA), heptanal and hexanal are 
significantly increased in the EBC patients with COPD in comparison with nonsmoking 
control subjects.14 Other compounds, such as nitric oxide, also be identified as a biomarker 
of various respiratory diseases including COPD. Researchers reported that the 
concentration of nitric oxide in COPD patients are consistently higher compared to healthy 
controls.15-17 Table 1.1 lists physiological origins of some endogenous breath molecules. 18   
Table 1.2 includes a summary of Lung Cancer-Related VOCs According to Recent 
Literature.19 For example, the compounds and their possible endogenous sources.  
Table 1. 1 
Physiological origins of some endogenous breath molecules 18 
 
Compound Physiological basis 
Acetaldehyde Ethanol metabolism 
Acetone decarboxylation of acetoacetate 
4 
 
Ammonia protein metabolism 
Carbon sulfide gut bacteria 
Carbon monoxide production catalyzed by heme oxygenase 
Carbonyl sulfide gut bacteria 
Ethane lipid peroxidation 
Ethanol gut bacteria 
Ethylene lipid peroxidation 
hydrocarbons lipid peroxidation/metabolism 
Hydrogen gut bacteria 
Isoprene cholesterol biosynthesis 
Methane gut bacteria 
Methanethiol methionine metabolism 
Methanol metabolism of fruit 
Methylamine protein metabolism 
Nitric oxide production catalyzed by nitric oxide 
synthase 
Pentane lipid peroxidation 
 
Table 1. 2 
Lung Cancer-Related VOCs According to Recent Literature19 
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2. Breath Sampling Methods 
Exhaled breath sampling is one of the most important steps in breath analysis and 
researchers should pay attention to a number of parameters, in order to avoid mistakes 
when make assumptions about the origin of the compounds identified. These parameters 
include the type and the number of breath collections, the portion of breath used, the breath 
storage and the interference of environmental VOCs from the collection place. Breath 
collection can be achieved through trapping a single breath or combining multiple breaths. 
Both methods have associated advantages, which should be taken into account before 
choosing one of the two. Overall, breath sampling is quick and simple, but the main concern 
is that the sampling should be totally comfortable and safe to patients when they provide 
exhaled breath. Since breath sampling can be performed easily, it allows large numbers of 
subjects to be studied. Different research groups reported different sampling methods. For 
example, the portion of breath being targeted can vary. The most usual techniques 
employed in pre-concentrating VOCs in air and exhaled breath are sampling of the air of 
breath in special recipients, collection in adsorbents as well as continuous sampling and 




Several types of containers, such as gas tight syringes, glass bulbs, stainless steel 
canisters and sampling bags, can be used for sampling and storing of breath samples. 
Syringes and glass bulbs are cheap and easy to use and clean, but they are also fragile and 
with a limited volume. Canisters (1000-3000 dm3) are made from stainless steel. The inner 
surface of the canister is electropolished to minimize adsorption and losses of target 
compounds. However, they are relatively heavy, bulky, expensive and require an effective 
cleaning procedure for multiple use. Currently, Tedlar sampling bags (made from PVF, 
polyvinyl fluoride) is one of the most commonly accepted materials for collecting gaseous 
samples in general and especially breath gas samples. 20,21 PVF is considered chemically 
inert to a wide range of compounds and adsorption of analyte molecules on its surface. 
Tedlar bags also are cheaper and relatively good durability and reusability. Other polymer 
bags such as Kynar, Flexfilm, Teflon (PTFE, polytetrafluoroethylene), Nalophan (PET, 
polyethylene terephthalate) and metal-coated multilayer bags (Flexfoil and polyester-
aluminum, PEA) are also used to store breath samples. Researchers have studied the 
stabilities of selected breath constituents in these three types of polymer bags and they 
found that the Tedlar bag has the best stability. 22 Another important advantage is that 
Tedlar bags can be reused for most applications, this will also save some experimental cost, 
which may be important to researchers. Prior to reuse, the Tedlar bags must be evacuated 
and thoroughly cleaned and flushed with purified air or nitrogen.  When the Tedlar bags 
are reused for analysis, it is recommended that this procedure be performed three to ensure 
that the background levels are acceptable for use.  
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Exhaled breath can also be sampled in its full composition (total breath sample or 
mixed expiratory air) or, alternatively, only the alveolar air may be sampled. The first 
choice has higher possibility to contaminations, since the sampling control is very deficient. 
The patient just breathes for the sample collection bags and therefore the risk of 
contamination with exogenous compounds from the oral cavity and dilutions in dead space 
are higher and may compromises the analysis. 23 These problems are reflected in the 
variation of the number of compounds and their concentration. In contrast, alveolar air is 
the part of exhaled air that has been in contact with blood inside alveoli. Dead space air 
does not enter the gas exchange region of the lung, which includes mouth, nose, pharynx, 
trachea and bronchi. 24  
2.2.Metal containers-single breath canister (SBC) 
In the 1990s, US Environmental Protection Agency (EPA) introduced the single 
breath canister method of exhaled breath collection. Beginning with the Total Exposure 
Assessment Methodology (TEAM) studies of the 1980s, EPA showed great interest in the 
use of breath sampling as an exposure assessment technique. They studied a series of 
population-based exposure assessment investigations designed to evaluate the most basic 
aspects of pollutant exposure. In the study, breath and blood samples were collected from 
volunteer subjects to determine which sampling technique would be most useful in 
determining exposures. The sampling through this method was clean, noninvasive and 
provided accurate information for many VOCs although this early method of exhaled 
collection is cumbersome. 25 
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This device comprised a stainless-steel canister that contained 1–1.6 L of alveolar 
breath. With single breath canister (SBC), carbon dioxide was generally measured as 4.6% 
of the exhaled breath, while the natural concentrations of isoprene and acetone served as 
markers to ensure that the collected sample was alveolar breath. 26 In general, the device 
was fitted with a Teflon tube for use as a mouth piece. 27 The subject was informed to close 
their lips around the tube before exhaling and the valve remained open until the end of 
expiration. An alveolar sample was obtained using the dead-space volume expelled before 
the valve was opened. The SBC had the advantage that unlike other end-tidal breath 
collection devices, these canisters are extremely durable and no special precautions are 
needed when shipping samples back to the laboratory.  
 




Sorbent tubes are the most widely used collection media for sampling hazardous 
gases and vapors in air, mostly as it relates to industrial hygiene. Sorbent tubes and traps 
are widely used in combination with gas chromatographic analytical methods to monitor 
the vapor-phase fraction of organic compounds in air. Figure 1.2 shows a detailed 
description of commercial sorbent tubes which are commonly used recently. 
 
Figure 1.2 A detailed description of sorbent tubes.29 
2.4.Bio-VOC breath sampler 
 Recently, the Bio-VOCTM breath sampler, a commercial sampling device, has been 
introduced and offers several advantages over the above techniques. A prototype of the 
Bio-VOC breath sampler was developed by the Health and Safety Laboratory (Sheffield, 
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UK)30 and commercialized by Markes International (South Wales, UK). The Bio-VOC 
breath sampler has three components: a mouthpiece, a volumetric sampler (tube/syringe) 
that retains around 100 mL air, and a plunger. A subject breathes through a disposable 
cardboard mouthpiece into the plastic Bio-VOC sampler, which has an open-end allowing 
air to be displaced as exhalation proceeds. Figure 1.3 shows a photograph of the Bio-VOC 
sampler with detailed information. As a result, the Bio-VOC sampler allows for the 
collection of alveolar air, the last portion of the exhaled breath, which is more likely to 
represent air from deep in the lungs. Once the breath collection is complete, the sampler is 
capped and VOCs are concentrated using SPME fibers, inserted into the sampler, 31,32 or 
on sorbent tubes, collected by discharging VOCs with a plunger onto tubed media. The 
sorbent tubes are most commonly used. Figure 1.4 shows a photograph of a Bio-VOC 
sampler, disposable mouthpiece, and sorbent tube. This device has now been used widely 
in human exposure assessments because of its convenience. 
A major limitation of the Bio-VOC sampler is the volume of the air collected. The 
reported volume for the device ranges from 100 to 150 mL,33,34 which is much lower than 
the volume collected with other sampling methods. However, no study has successfully 
measured the actual volume of air collected using the Bio-VOC sampler. However, no 






Figure 1.3 (a) Photograph of the sampler; (b) cross-sectional diagram through the breath 
sampler: ①mouth piece, ②outer ring, ③non-return valve, ④outer tube, ⑤adsorption 





Figure 1.4 Photograph of a commercial Bio-VOC sampler, disposable mouthpiece, and 
sorbent tube.36 
2.5.Exhaled breath condensate (EBC)  
Exhaled breath condensate (EBC) is formed through condensation of cooled 
exhaled breath and has been analyzed for a variety of mediators, including hydrogen 
peroxide, lipid mediators, purines, and cytokines. Exhaled breath condensate (EBC) is also 
a promising source of biomarkers of lung disease. It is important to note that EBC is not a 
biomarker, but rather a matrix in which biomarkers may be identified, in that way 
equivalent to blood, sweat, tears, urine and saliva. EBC may be thought of either as a body 
fluid or as a condensate of exhaled gas (and therefore not a body fluid). This issue is 
relevant because of potential government regulatory issues involved with laboratory 
assessment of “body fluids”.25 
There are three principal contributors to EBC.37 The first is variable-sized particles 
or droplets that are aerosolized from the airway lining fluid such particles presumably 
reflecting the fluid itself. The second is distilled water that condenses from gas phase out 
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of the nearly water-saturated exhalate, substantially diluting the aerosolized airway lining 
fluid. The third is water soluble volatiles that are exhaled and absorbed into the condensing 
breath. 
Exhaled breath condensate (EBC) has been proposed as a non-invasive means of 
measuring airway inflammation. Unlike traditional methods of sampling secretions from 
the lower respiratory tract such as bronchoalveolar lavage, EBC analysis has the advantage 
of being simple to perform, may be repeated frequently, and can be applied to patients 
during both the stable and exacerbation phase of disease. The condensate derives from 
expired water vapor and volatile gases, but the presence of non-volatile solutes suggests 
that droplets of airway lining fluid have also been collected due to aerosolization during 
turbulent airflow. Analysis of these solutes may potentially provide insights into the 
pathophysiology of lung diseases such as asthma,38,39 cystic fibrosis,40,41 and chronic 
obstructive pulmonary disease.42,43 
While exhaled breath condensate shows promise as a source for biomarkers in 
pulmonary diseases, large variabilities in the concentration of solutes in EBC samples with 
considerable overlap between normal subjects and disease groups have been reported.43 
With absence of supporting data, much of the differences have been attributed to variations 
in the proportion of water vapor diluting the airway lining fluid or variations in flow 





Figure 1.5 Schematic of apparatus and instrumentation for measurement of total exhaled 
water and collection of exhaled breath condensate.44 
 
 Figure 1.5 shows a schematic of an apparatus and instrumentation for measurement 
of total exhaled water and collection of exhaled breath condensate. 44 Subjects breathe 
through a non-rebreathing two-way valve at a pattern set by the ventilation targeting system 
which generates an audio visual feedback signal setting ventilatory rate and expiratory flow, 
respectively. An air conditioning unit controls the temperature and moisture content of the 
inspired air. Temperature and humidity sensors are located as shown. 44 
Several options exist for collection of EBC samples. Multiple custom devices have 
been used throughout the years, using various cooling techniques and device shapes and 
16 
 
materials. In terms of parts-which are often found about a respiratory laboratory-such 
homemade systems often can be made cheaply, although the expense in terms of personnel 
time may be surprisingly substantial. Commercially available equipment is also available 
as shown in Table 1.3. 45 
The whole process of breath analysis contains sampling, pre-concentration, 
measurement and data analysis as showed in Figure 1.6. So here we discussed different 
sampling methods recently used, then different pre-concentration methods were introduced 
following.  
Table 1. 3 




Manufacturer Advantages Disadvantages 
ECoScre





Most commonly published EBC 
collection system. More common 
in European centers. Optional 
package for determination of 
total exhaled volume. 
Not readily portable. 
Cleaning between 
patients may need to be 
extensive to abide by 
standard respiratory 
care practices. No 






More total EBC collections 
performed using RTube than 
other systems. Multiple 
collections can be performed 
concurrently. More common in 
North American centers. 
Disposable (no cleaning between 
patients). Portable. Can be 
prepared for use in a standard 
freezer. 
Choice and 
maintenance of set 
condensing temperature 
requires optional 
cooling unit, otherwise 
condensation 
temperature is chosen 
by cooling sleeve 
preparation temperature 






Controllable temperature of 





Italchil, Italy Has both non-disposable and 
disposable portions. Controllable 
collection temperature. 
Moderately portable. Readily 
cleanable because of disposable 
components. 
Few publications. 
Simple system. One 





Figure 1.6 A diagram illustrating the off-line breath sampling pipeline.46 
3. Preconcentration Techniques 
As mentioned above, the concentrations of VOCs in exhaled breath are very low. 
Therefore, small interfering compounds could affect the analytical results. To minimize this 
interference, an intermediate step between sampling and analysis is sometimes necessary and 
advantageous to increase the concentration level of the target analytes over the possible 
interfering compounds. There are several concentration techniques available, such as cryogenic 
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trapping, usually used with the canister breath sampling, and adsorption in different thermal 
desorption tubes (TD-tubes), sorbent traps and coated fibers. The adsorption option requires a 
thermodesorption step, being usually followed by gas chromatography combined with mass 
spectrometry (GC/MS). Commonly used pre-concentration methods include sorbent-
containing thermal desorption (TD) tubes, the employment of solid phase microextraction 
(SPME), as well as needle trap devices (NTDs).  
3.1.Thermal desorption (TD) tubes 
TD tubes are popular for pre-concentration of VOCs and account for almost half of 
the pre-concentration methods published to date. Sorbents can be manually packed into the 
tubes or tubes can be purchased pre-packed from suppliers. Commonly used sorbents 
include Tenax TA&GR, Carbograph 5TD, Carboxen. Due to the distinct properties of these 
materials there is much variability in the range of volatiles that are trapped. Sample volume 
should be considered in order to prevent breakthrough and subsequent loss of analytes. 
Strong sorbents such as Carboxen are suitable for trapping very volatile organic 
compounds(C2-C4) while Tenax sorbents trap less volatile VOCs in breath (C7-C15). 47 
Whether to use single or multi-bed sorbents which will depend on analytes of interest, and 
also the quantity of sorbent used.  
When breath has been temporarily stored in polymer bags, VOC-capture proceeds 
by attaching one end of the TD tube to the bag and the other end to a pump which functions 
to pull gaseous breath from the bag across the sorbent. Although the use of these sorbent-
containing TD tubes is stated to be highly sensitive, it will cost a lot of time. Also, sorbents 
like Carboxen are hydrophilic thus retain moisture which can negatively affect the 
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quantitative capture of some analytes. Introducing a dry purging step especially when using 
a hydrophilic sorbent may be a solution.  
3.2.Solid phase microextraction (SPME) 
Solid-phase microextraction (SPME) has been applied to the quantitative 
determination of ethanol, acetone and isoprene in human breath. Solid-phase 
microextraction (SPME), originally developed by Pawliszyn et al.,48,49 is a rapid, 
inexpensive, and efficient technique for sampling solid, liquid, or gaseous samples. It 
requires no solvents or complicated apparatus and provides linear results over a wide range 
of analyte concentrations. Analysis of the extracts is performed using GC, GC/MS, or 
HPLC. 48,49 In the SPME technique, a fused silica fiber coated with a polymeric stationary 
phase is contained in a specially designed syringe whose needle protects the fiber when 
septa are pierced.   Figure 1.7 shows a SPME device modified for breath analysis. 49 The 
fiber is directly exposed to a liquid or gaseous sample to extract and concentrate the 
analytes. After the absorption equilibration is attained, the fiber is withdrawn into the 
needle and introduced into an injector of a gas chromatograph, where the extracted 
compounds are thermally desorbed and analyzed. SPME can be performed manually or by 
an autosampler. The method is economical, because one single fiber can be used repeatedly. 
Unlike in conventional methods for analysis of gaseous samples, modified equipment like 
a complex valve injection system, a thermal desorption device, or a cooling trap is not 
required by SPME. The SPME fiber is easily cleaned by desorbing any contaminants in a 
hot GC injector. The SPME technique coupled with GC has been used to analyze volatile 
and semivolatile air compounds. The fiber can be exposed directly to the air or to a sample 




Figure 1.7 SPME device modified for breath analysis.49 
3.3. MEMS preconcentrator devices 
Many efforts are being made to develop a microfabricated GC system (μGC) that 
is small enough to be carried by individuals. A micro pre-concentrator (µPC) is a key 
component in such a device. The µPC increases the concentration of analytes from low 
concentration (e.g. parts-per-billion) to higher concentrations (e.g. parts per million) so that 
low concentrations of analytes can be detected. 50 Micro-PCs, including a heated membrane 
with a thin adsorbent layer, were developed by Frye-Mason et al. for detecting specific 
chemical warfare agents. 51 Tian et al. developed a multiple-stage microfabricated PC with 
a large adsorbent capacity.52,53 
A new type of fully integrated MEMS µPC that has been fabricated and tested for 
the rapid concentration of vapor species are introduced to a flame ionization detector (FID). 
A one microliter size µPC filled with polyethyleneimine (PEI) coated microposts is 
integrated with fast microvalves 54 (response time < 50 µs) and a resistive microheater 
(ramping to 200 ºC in 0.5 seconds).55 The integrated PC can sample a cubic centimeter of 
gas in 0.2 seconds with an 50 kPa inlet pressure, adsorb targeted species, heat and desorb 
them in 0.5seconds, and inject the now concentrated gaseous species using fast acting 
microvalves in pulses as small as 50 microseconds into separation columns in a µGC, or 
directly into a detector. The unprecedented speed of this µPC (< 1 s) is enabled by MEMS 
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sizing and fabrication, allowing sniffing of phosphonates, toxic industrial compounds 
(TICs), and other volatile compounds in seconds, rather than tens of minutes with 
conventional systems. The micropost structures, which are subsequently coated with PEI, 
are fabricated using deep reactive ion etching to achieve a high surface area-to-volume 
ratio while permitting a relatively low pressure drop during the loading and injecting phases 
of operation in order to reduce both power consumption and analysis time. 56 
 
Figure 1.8 (a) A schematic cross-sectional diagram of the integrated preconcentrator 
consisting of a NiCr microheater, a 1µL preconcentrator, and two microvalves. (b) Device 
picture of the layers corresponding to (a).57 
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Figure 1.8 shows a schematic diagram and device pictures of the integrated µPC. 57 
It consists of a NiCr microheater, the posted preconcentrator cavity, and two electrostatic 
microvalves. The NiCr microheater heats the silicon surface immediately adjacent to the 
µPC to subsequently heat the gas and analyte up to 200 °C using a feedback control of 
resistance-temperature relationships obtained in off-line calibration. The microvalves are 
composed of a valve seating electrode, whose topside the µPC is integrated within, a 
membrane electrode, and a valve opening electrode. The membrane electrodes located at 
the inlet (A) and outlet (B) of the µPC, respectively, are opened by applying a voltage V1 
and closed by applying V2, as shown in Figure 1.9. 57   This feature enables the injection 
band width from the µPC to be controlled by the operation of the microvalves, rather than 
by a slower desorption heating rate. Portable gas chromatographs or micro-gas 
chromatographs (μ-GCs) provide an analytical tool that permits a quick analysis of volatile 
organic compounds (VOC) for online monitoring. Figure 1.9 illustrates the (a) on and (b) 
off operation of the microvalves, as well as important features contributing to a switching 
performance on the order of microseconds. These features include pneumatically balanced 
membranes (by P1), which is designed to have almost zero net pressure across the 
membrane to handle increasing pressures, and center pads which are designed to increase 




Figure 1.9 (a) A schematic diagram of the PC when the valves are opened, and (b) closed.57 
The development of μ-GC system has driven an important research effort. Portable 
gas chromatographs or micro-gas chromatographs (μ-GCs) provide an analytical tool that 
permits a quick analysis of volatile organic compounds (VOC) for online monitoring. 
Adding a preconcentration step should allow increasing the sensitivity of miniaturized 
analyzer.58 The SRA Instruments Company developed and commercialized a MEMS gas 
preconcentrator into a µ-GC module. Some research experiments conducted with a 
preconcentrator filled with carbon nanopowder and compled to a micro chromatograph 
have shown an accurate separation and identification of various trace VOCs within a gas 
mixture. 
The device developed by C. Pijolat et al.59 is a silicon microchannel (20 × 85 mm2, 
thickness 500μm) obtained by deep reactive ion etching (DRIE) and designed with fluidic 
micro-structures at the inlet/outlet leading to a preconcentration chamber with a volume of 
14 μl. The microchannels were produced on a 5 Ω·cm, n-type, (100)-oriented 1mm µm-
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thick silicon wafers. The first step of the fabrication was the DRIE with a thick photoresist 
used as an etching mask. Then the micro-channels were bonded with a PyrexR glass wafer 
by anodic bonding. Finally capillaries were sealed at the inlet/outlet with ceramic cement 
and a glass paste. The inlet/outlet has a depth of 500 µm, corresponding to the diameter of 
the capillaries used as fluidics interconnections.59  
The preconcentrator allows desorbing at relatively high temperature (230 °C) all 
the molecules collected after an adsorption step made at ambient temperature thanks to an 
adsorbent which is described. Figure 1.10 shows that on the backside of the silicon device, 
a platinum resistance was screen printed to act as a heater with a heating rate of 40°C/min. 
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Figure 1.10 Design and schematic device composition; (a) platinum heater, (b) MEMS, (c) 
glass cover, (d) capillaries.60 
4. Analytical Methods  
The detection and quantification of extraordinarily low concentrations of non-
volatile biomarkers/compounds in EBC requires highly sensitive analytical methods. 
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During the last decade, separation methods have become the method of choice for the trace 
analysis of various compounds contained in complex biological matrices. 
4.1.Gas chromatography (GC) 
The most popular method employed for the analysis of trace components in human 
breath has been GC or its combination with flame ionization detection (FID), MS, or ion-
mobility spectrometry (IMS). In fact, almost all the exhaled breath VOCs reported so far 
have been identified and quantified using MS-based methods, most often GC-MS.61 GC-
MS is possibly the most common and comprehensive approach to characterize exhaled 
breath volatile organic compounds. It allows the selective analysis of one or simultaneous 
analysis of many compounds that may be in the range from ppb to ppt. The GC-MS 
involves separation of volatilized samples in chromatographic column based on different 
parameters, such as the boiling point of the sample components or polarity of the GC 
column. GC-MS system ionizes the target ions, separate them by mass to-charge (m/z) 
ratios and uses the resolved fragmentation patterns to quantify the amount of each specific 
VOC in the sample. However, there are other detection systems that have been coupled to 
GC for breath analysis, namely FID and IMS. In the FID detection system, VOCs are 
burned in the FID, producing ions and electrons that can conduct the electric potential and 
this information is used for detection and eventually quantification. The advantages of GC-
FID system are high sensitivity, large linear response range and low noise. However, the 
GC-FID system also has disadvantage that the FID detector is mass sensitive and its 
response is not altered significantly by changes in mobile-phase flow rate. In turn, in the 
GC-IMS system, ions are separated according to their mobility as they travel through a 
purified gas, in an electric field at the atmospheric pressure. The IMS detector is also 
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selective, allowing the quantification of VOCs in the exhaled breath. Regardless of the 
detection method used in a GC analysis, this approach presents, however, some drawbacks, 
for example, the requirement for sample pre-treatment (sampling and pre-concentration). 
Therefore, a GC analysis is only suitable for indirect sampling and not for real-time 
analysis, also the GC analysis usually takes hours, a time-consuming process. Thus, the 
important concerns inherent to the sample pre-treatment that need to be carefully addressed 
to improve the quality of the data obtained in a GC analysis are analytes loss and 
degradation, particularly of those of reactive or thermally labile metabolites, and possible 
contaminations.62-65 Figure 1.11 shows that GC-MS chromatography has been also used 
for the identification of metabolic end products including pentane, acetone, ethanol, 
isoprene and other VOCs in normal human breath.  
 
Figure 1.11 Normal human breath chromatogram of GC-MS.66 
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4.2.Selected ion flow tube mass spectrometry (SIFT-MS)  
Selected ion flow tube mass spectrometry (SIFT-MS) is a new analytical technique 
for the real-time quantification of several trace gases simultaneously in air and breath. It 
relies on chemical ionization of the trace gas molecules in air or breath samples introduced 
into helium carrier gas using H3O
+, NO+, and O2
+ precursor ions. Reactions between the 
precursor ions and trace gas molecules proceed for an accurately defined time, the 
precursor and product ions being detected and counted by a downstream mass spectrometer, 
thus effecting quantification. Absolute concentrations of trace gases in single exhaled 
breath can be determined by SIFT-MS down to ppb levels, obviating sample collection and 
calibration. Illustrative examples of SIFT-MS studies include (i) ethanol metabolism, 
exogenous compounds, elevated acetone during ovulation and breath and urinary 
headspace studies of metabolites; (ii) analysis of gases from combustion engines, animals 
and their waste, and food; and (iii) urinary infection and the presence of tumors, the 
influence of dialysis on breath ammonia, acetone, and isoprene, and acetaldehyde released 
by cancer cells in vitro. Figure 1.12 shows the principle of the SIFT technique. 49 The ions 
listed in the flow tube are the precursor ions (upstream) and examples of the product ions 




Figure 1.12 A schematic of the SIFT used for the study of ion-molecule reactions. When 
configured to measure trace gases in air or breath samples it becomes a SIFT-MS.  
4.3.Proton transfer reaction mass spectrometry (PTR-MS) 
PTR-MS is a relatively new technique developed by Lindinger et al.67,68 for use in 
breath research, but very promising because it can deliver results in a real-time online 
measurement, with high sensitivities for VOCs detection and quantification (up to the pptv 
range). PTR-MS uses H3O
+ ions for proton-transfer reactions with many common VOCs, 
while having little to no reaction with the highly abundant atmospheric gases (N2, CO2 and 
H2O) that compose more than 99% of exhaled breath.
67,68 PTR-MS is advantageous for 
complex gas mixtures (like breath samples), as it does not require pre-concentration and 
separation of samples prior to analysis. The instrument also has very high sensitivity due 
to the high intensity and relatively high purity of the primary H3O
+ that allows the injection 
of higher currents of reagent ions directly into the drift region without prior mass selection. 
It is demonstrated that PTR-MS can be used to determine the concentrations of about 30 
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VOCs at a sensitivity of a few tens of ppt level (in 2 min).68 PTR-MS is suitable for non-
invasive, on-line observation of biochemical reactions in the human body. This type of 
approach is demonstrated to offer some insights into metabolic processes that were 
previously inaccessible. However, there are a few disadvantages of PTR-MS, for example, 
the limit of detection and the number of compounds that can be simultaneously analyzed. 
Further, it is also impossible to separate nominally isobaric VOCs using the classic PTR-
MS since these compounds all result in protonated molecules via proton transfer reactions 
with H3O
+. 69According to Herbig et al.,70 in order to resolve individual phases, it is 
necessary to have a minimum of 3 Hz of sampling frequency in an online breath analysis. 
Thus, this trade-off between the signal-to-noise ratio (S/N) and the number of measured 
m/z limits the number of compounds that can be simultaneously monitored and the 
respective limit of detection (LOD) that can be obtained.  
4.4.Electronic nose 
Array-based gas sensors (“Electronic Nose”) now offer the potential of a robust 
analytical approach to exhaled breath analysis for medical use. Electronic noses rely on 
chemical vapor sensor arrays that respond to particular chemical characteristics of 
individual molecules, such as VOCs. By analyzing the data obtained from the sensor arrays 
using statistical or structural algorithms, we can discriminate and identify volatile patterns. 
The advantages of electronic nose compared to other analytical methods for breath analysis 
are revealed to be rapid, simple and promising for reducing the time and costs of an early 
diagnosis of the investigated diseases.  
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The most updated electronic nose system used for breath analysis is shown in 
Figure 13. It is comprised of an array of six commercial chemical gas sensors: MQ-2, MQ-
3, MQ-9, MQ-135, MQ-137 and MQ-138.71 The selection of the gas sensors was based on 
their sensitivity and selectivity towards different gaseous compounds that can be found in 
the exhaled breath. In this system, the sensors’ limit of detection is sometimes below the 
VOC’s concentration present in breath, so the use of a sensor array distinguishes between 
the investigated diseases. Immediately after breath collection, the samples were transferred 
to sensors chamber by pumping the content of each bag at a constant flow rate of 
200mL/min. Each sensor underwent a reversible change in its electrical resistance upon 
exposure to exhaled breath. During the experiment, a relative humidity sensor was used for 
constantly monitoring this parameter. The total acquisition time for all sensor signals are 5 
minutes. Data acquisition system was accomplished using a PCI-6221 and a DAQ interface 
running on the computer for visualizing and saving the data provided by sensors. Figure 
1.13 shows the experimental set-up of a e-nose system.  
 
Figure 1.13 Experiment set-up of e-nose system equipped with data acquisition software 
used in exhaled breath measurement.71 
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5. Lung Cancer Biomarkers In Exhaled Breath    
Table 1.4 shows a summary of lung cancer biomarkers researchers have found in 
recent years. For examples, in 2014, Fu’s group used FT-ICR-MS method to detect the 
carbonyl VOCs in exhaled breath of lung cancer patients and healthy controls. They found 
that 4 different biomarkers can be used to distinguish the lung cancer patients from healthy 
controls. They also define the cut off concentration range for the 4 biomarkers.77 In 2013, 
Broza group using SPME/GC-MS method also found that 3 biomarkers for lung cancer 
patients although they did not provide the cut off concentration range of these compounds.  
Table 1. 4 
Characterization of selected exhaled breath (EB) volatile organic compounds (VOCs) 
reported in the literature 
Author, Year Disease Detection 
Method 


























































  Zou, 201478         Lung Cancer     GC/MS         Hexadecanal                   < 2-10 ppb 
                                                                             Hexylpentadecane          72-81.5ppb 
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 0.00672 nM 
 0.1595 nM 
 0.3875 nM 
Fernandes, 
201581 
Lung Cancer GC/MS Acetaldehyde 
Isopropene 
< 2-10 ppb 
72-81.5ppb 
 










6. Dissertation Organization    
This dissertation includes six chapters. Chapter 1 provides a review of different 
methods of detection and analysis of volatile organic compounds in exhaled breath. 
Chapter 2 investigates different design of microreactors and characterizes them and the 
kinetics studies of oximation reactions of the aminooxy reagent ATM. Chapter 3 studies 
the stability of breath VOCs in Tedlar bags. Chapter 4 investigates exhaled breath samples 
of the patients from Floyd Memorial Hospital and finds that C3H6O, C2H4O2 and C4H8O2 
can serve as biomarkers to distinguish patients with pulmonary nodules from healthy 
controls. Chapter 5 analyzes exhaled breath samples of the lung cancer patients, patients 
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with benign pulmonary nodules and healthy volunteers and found three VOCs (2-butanone, 
3-hydroxy-2-butanone and 4-hydroxy-2-nonenal (4-HNE)) to distinguish LC from patients 
with benign pulmonary nodules and healthy controls. 4-HNE can also be used to 
distinguish squamous cell carcinoma from adenocarcinoma LC. Chapter 6 provides a 










In recent years, many studies have shown that certain ketones and aldehydes in 
human breath could be used as biomarkers for noninvasive diagnosis of lung cancer. PTR-
MS and SIFT-MS detected ketones and aldehydes in human breath without any 
preconcentration process.83-86 The most difficult part for PTR-MS and SIFT-MS, however, 
was to identify compounds with certainty since several compounds overlaped on a specific 
mass-to-charge ratio. Solid phase microextraction (SPME) with adsorbed O-2, 3,4,5,6-
(pentafluorobenzyl) hydroxylamine hydrochloride (PFBHA) has been used for analysis of 
aldehydes in human breath. SPME was introduced as a rapid extraction technique for 
analysis of volatile compounds from a variety of matrices and it was a popular 
preconcentration method a decade ago. But the SPME method has one major disadvantage, 
which is its small surface area for reaction. 87-91 The preconcentrators fabricated on silicon 
wafers using microelectromechanical system (MEMS) technology typically consist of a 
microhotplate and an adsorbent placed adjacent to the heating element. Physical adsorption 
for preconcentration of trace VOCs and thermal desorption to release the adsorbed VOCs
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procedures were used for MEMS preconcentrators.10,11 However, MEMS-based 
preconcentrators have low physical adsorption efficiency and poor selectivity issues. The 
drawbacks for electronic nose are its low sensitivity and specificity for detecting lung 
cancer. Exhaled breath condensate (EBC) provides a convenient and non-invasive method 
for sampling of the airway lining fluid of the respiratory tract, but it is easy for volatilization 
so it is hard to detect when operating. The exhaled breath is easy to degrade with analysis 
time increasing, so the most important thing for improving accuracy is to decrease the 
sample process time as short as possible.92-95 
In this chapter, we describe a fabricated microreactor with custom-engineered 
surface functionality for preconcentrating ketones and aldehydes in exhaled breath as 
cationic derivatives through oximation reaction instead of physical adsorption. The 
custom-engineered surface functionality was realized by adsorbing quaternary ammonium 
aminooxy salt, 2-(aminooxy) ethyl-N, N, N-trimethylammonium iodide (ATM), on the 
surfaces of micropillars in the microreactor. Then we use methanol flow through the 
microreactor so that the entire trapped analytes can be eluted out and directly analyzed by 
UHPLC-MS system. In order to decrease the time for analysis, we designed different 
structures of microreactors. The width of the microreactors was unchanged. The difference 
is the length; we set 7mm as a unit for length. Then we fabricated microreactors with 
lengths of 7mm, 14mm, 21mm, 28mm, and 42mm. All microreactors were then tested for 
capture of ketones and aldehydes. We also changed the air flow rate through the 
microreactor to decrease the time for analysis. If we can get same capture efficiency in a  
very fast flow rate with the longer microreactor compared to the microreactor with 7mm 
in length with very slow flow rate, then this will be a significant improvement. After testing 
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this, we use chemical reaction engineering theory to set up a model that can be used to 
predict the effect of length and flow rate with capture efficiency.  
 
2. Design and Fabrication 
The design and fabrication process are referring to the procedures of the MEMS 
device. The design contains 16 microreactors, and each microreactor has a microfluidic 
channel that has micropillars of circular and triangular shapes. Figure 2.1 shows four screen 
shots of the photomask design. Figures 2.1.a&b show the dimensions of the devices, the 
channel is 7mm in width, 14mm and 21 mm in length. Figures 2.1.c&d show the design of 
the circular and triangular micropillars. The circular micropillar has a diameter of 50 µm 
and the gap between the pillars is 10 µm. Each side of the triangular micropillar is 50 µm 














Figure 2.1 (a) Layout for a microreactor with a channel of 14 mm long and 7 mm wide. (b) 
Layout of microreactor with a channel of 21 mm long and 7 mm wide. (c) Layout of the 
triangular micropillars. Each side of the triangular micropillar is 50 µm and the gap 
between the adjacent triangles is 10 µm. (d) Layout of the circular micropillars. The 
diameter is 50 µm and the gap between the micropillars is 10 µm. (e) Mask layout of 21mm 
length microreactor. 
Figure 2.2 illustrates the fabrication steps used to produce the microreactors. The 
fabrication process was done in the cleanroom of the Micro/Nano Technology Center 
(MNTC) at University of Louisville. The wafer used for the microreactor fabrication was 
100mm in diameter, 1000 µm in thickness, <100> p type single side polished silicon wafer. 
The resistivity of the wafer was 1-20 Ω-cm. The wafer was successively rinsed using 
acetone, methanol and then deionized (DI) water, dried using a stream of pure N2 gas, and 




patterned on the wafer using a photomask containing 16 microreactors. The microreactor 
had microchannels that contained micropillars with circular and triangular shapes. These 
micropillars were created by using Deep Reactive Ion Etching (DRIE). The micropillars 
were thermally oxidized to form an oxidation layer with a thickness from 50 to 100 nm. 
The last step was bonding the oxidized wafer with Pyrex glass wafer using an anodic wafer 
bonding process. The bonded wafers were diced into separate microreactors. Fused silica 





Figure 2.2 Fabrication process to create the microreactors. (A) Bare silicon wafer. (B) 
Photoresist patterning using UV exposure. (C) Photoresist development using MF319. (D) 
Micropillars formation using Deep Reactive Ion Etching. (E) Thermal oxidation of 
thickness 50 nm to 100 nm. (F) Anodic bonding of Pyrex glass and the oxidized wafer. 
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Details of the fabrication steps are as follows. 
2.1 Photoresist patterning 
A positive photoresist MEGAPOSIT® SPR ® 220 7.0 was coated on the prepared 
silicon wafer at a spin speed of 500 RPM for 1 second and a spread speed of 4000 RPM 
for 30 seconds. The wafer is soft baked at 115°C for 2 minutes. After exposing to the UV 
source for 55 seconds exposure at 12W/cm2 through a photomask on a Karl Suss contact 
aligner, the wafer is developed in MF319 solution for 90 seconds. The wafer is observed 
under optical microscope to check whether the patterns are of channel and pillar arrays 
match the photo mask. If not, the wafer is washed by acetone, methanol and DI water to 
remove the residual photoresist, blew dry by pure N2, heat up at 115°C for 2 minutes and 
redo the photolithography process. After development, the wafer is hard baked at 115°C 
for 5 minutes. The hard-baked photoresist was used as a protective mask during the etching 
process. Figure 2.3 shows the microscopic images of the micropillars. The photoresist 


















2.2 Silicon etching using deep reactive ion etching 
The 370±10 µm height micropillars in the microreactor channel were defined by 
deep reactive ion etching (DRIE) using STS silicon DRIE machine. The gases used were 
Sulfur Hexoflouride (SF6) and Oxygen (O2). The plasma was generated using R.F. signal 
of frequency 13.56 MHz and power of 800 Watts. The etching time was 83 minutes. The 
depth of the channel and the height of the micropillars are checked using profilometer. The 
wafers were put in N-Methyl-2-pyrrolidone (NMP) bath to strip the photoresist followed 
by oxygen plasma in the March RIE etcher for 1 minute to completely remove any 
photoresist residues at a condition of  300 watts, Pressure 300 mTorr O2 flow (20% sccm). 
Figure 2.4 shows the optical images of the devices were taken using a stereo microscope 





















Figure 2.5 SEM images of the cylindrical, diamond, square and triangular shape 
micropillars. 
2.3 Thermal oxidation 
The wafer is oxidized to form a 50 nm SiO2 layer on the micropillar surfaces in a 
“wet” O2 and H2O atmosphere in a thermal oxidation furnace at 1000°C for 12 minutes.  
The oxide layer thickness was measured using a FILMETRICS system. 
2.4 Bonding and dicing 
The wafer was sealed by anodic bonding with a glass wafer using Suss bonder. 
Subsequently, the wafer is diced and the connection ports are opened. 
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2.5 Silica tube mounting 
The inlet and outlet of the microreactor were connected with 360 µm O.D., 250 µm 
I.D. deactivated fused silica tubes using 3MTM Scotch-WeldTM Instant Adhesive CA4. 
Figure 2.6 shows the microreactor connected with silica tubes compared to a dime dollar. 
 
Figure 2.6 The picture of 21mm length microreactor compared to a US ten-cent coin. 
 
3. Materials and Setup 
All reagents and solvents, including deuterated acetone (acetone-d6) (99.9%), 
acetone (99%), 2-butanone (99%), 2-pentanone (99.5%), pentanal (99%), acetaldehyde 
(98%), and methanol (99.9%), were purchased from Sigma-Aldrich. The quaternary 
ammonium aminooxy compound ATM was synthesized by professor Nantz’s group at 
University of Louisville using the literature procedure.137 
The quaternary ammonium aminooxy salt, ATM was used as a “capture phase” by 
coated to the micropillars to trap ketones and aldehydes via oximation reactions. Figure 2.7 
shows that schematic illustration of oximation reaction of ATM to capture ketones and 
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aldehydes in the microreactor. The surface functionalization of the channels and 
micropillars with 2-(aminooxy)-N,N, N-trimethylethanam-monium (ATM) iodide was 
performed by infusion of ATM iodide in methanol solution of known concentration from 
a 2mL vial into the microreactor from one connection port followed by evaporation of the 
solvent under vacuum. The electrostatic binding of the cationic ATM on the surfaces of 
the micropillars can be done by the slightly negative surface charge of the silicon oxide 
micropillars. ATM reacts chemoselectively with trace carbonyl VOCs in exhaled breath by 
means of oximation with high reactivity. This approach is suitable for quantitative analysis 
of ketones and aldehydes in exhaled breath. For rapid analysis and identification of trace 
VOC adducts in a microliter volume sample, UHPLC-MS system was used in the 
experiment.  
 
Figure 2.7 Schematic illustration of ATM oximation to capture ketones and aldehydes in 
the microreactor. 
Figure 2.8. Shows the illustration of the instrument set up. A microreactor is 
connected to a Tedlar bag (Sigma-Aldrich, St. Louis, MO) which contains the air sample 
from synthetic air in a cylinder. We can adjust the flow rate by using a mechanical needle 
valve. The flow rate of the sample through the microreactor can be measured by a flow 
meter. In these experiments, we use a flow meter to set different flow rates: 3.5mL/min, 
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5mL/min, 7mL/min, 8mL/min, 10mL/min, 15mL/min and 20mL/min. The microreactor 
was loaded 30μL ATM in methanol solution which is 1.5μmol in advance and dried in an 
oven with 60 kpa vacuum and 50 °C over night.  
Air and exhaled breath samples were collected in 1-L Tedlar bag. The detailed 
protocol for collection of exhaled breath samples was approved by the Institutional Review 
Board (IRB) at the University of Louisville. For the characterization of different types of 
microreactors, 1-L N2 collected from a cylinder as carrier gas was infused into Tedlar bag. 
Then use syringe to add 5μL standard solution to Tedlar bag. The 5μL standard solution 
contains 5nmol of each acetaldehyde, pentanal, 2-butanone and 2-pentanone. For the flow 
rate through the microreactor, we use flow meter to change the valve until the flow rate is 
3.5ml/min. After preparing the samples, the Tedlar bags were collected to the inlet port of 
the microreactor through one fused silica tube. The exit port of the microreactor was 
connected to a vacuum pump through the other fused silica tube on the microreactor as 
shown in Figure 2.8. Then turn on the vacuum pump to pull gaseous sample from a Tedlar 
bag through the ATM-coated microreactor. After evacuation, disconnect the microreactor. 
Finally, the reacted ATM adduct and unreacted ATM are eluted from the microreactor by 
flowing 150 μL methanol from one slightly pressurized vial through the microreactor and 
then into an empty collecting sample vial. Figure 2.9 shows a process of elution. The eluted 
solutions were directly used for UHPLC-MS analysis without any further process. A 
known amount of deuterated acetone completely reacted with ATM (ATM-acetone-d6) in 
methanol was added to the eluted solution as an internal reference (IR). The amount of 
captured compounds was determined by comparing the UHPLC-MS signal abundance of 
ATM-acetone-d6 with that of reacted ATM-ketone and ATM-aldehyde. The capture 
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percentage can be determined by dividing the amount of captured ketones or aldehydes by 
the added amount of carbonyl compounds in the Tedlar bag. Then test the flow rate of 
5mL/min, 7mL/min, 8mL/min, 10mL/min, 15mL/min and 20ml/min to obtain the capture 
efficiency at different flow rates.  
 
Figure 2.8 Schematic flow diagram of the evacuation process setup.  
 
Figure 2.9 Elution of reacted ATM adducts and unreacted ATM from the microreactor. 
4. Results and Discussion 
Besides the flow rate effects on capture efficiency, we also designed experiments 
to study whether the distance between micropillars and different pillar shapes affect capture 
efficiency. For the pillar distance effect experiment, we designed 3 different distance 
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micropillars, 10µm, 25µm and 50µm. We also designed the 4 different shapes micropillars, 
triangle, circle, diamond and square shape.  
1.5×10-6 mol of ATM in methanol was loaded into the microreactor and dried, then 
5×10-9mol 2-pentanone, 2-butanone, acetaldehyde and pentanal dissolved in 5μL methanol 
were injected into 1L Tedlar bag which contain 1L pure nitrogen. Then the samples were 
evacuated through the microreactors under vacuum. After evacuation, ATM-carbonyl 
adducts were eluted from the microreactors with 150 µl methanol to afford ≥ 99% recovery 
of adducts. The eluted solution was analyzed by UHPLC-MS system. Figure 2.10 (a) shows 
that for the microreactors with cylindrical micropillars, as the flow rate increases from 2.5 
ml/min. The capture efficiencies of 2-butanone, 2-pentanone, acetaldehyde and pentanal 
all are linearly decreased. Figure 2.10 (b) shows that as the gap between micropillars 
decrease from 50µm to 10µm, the capture efficiencies of 2-butanone, 2-pentanone, 
acetaldehyde and pentanal all are linearly increase. We also examined the micropillar shape 
effect on the capture efficiency. Figure 2.10(c) show four different shapes of the 
microreactors with the capture efficiencies. The shape of triangle has the highest capture 
efficiency. After these experiments, we conclude that the smaller the micropillar distance, 
the higher capture efficiency. High flow rate will decrease the capture efficiency and the 
triangular shape micropillars can achieve the highest capture efficiency. After this study, 
we find the optimal design of microreactors for capture trace ketones and aldehydes. So in 
the following research, we designed optimized microreactors with the triangular shape of 
















Figure 2. 10 (a): Relationship between capture efficiency and flow rate of the microreactors 
with cylindrical micropillars, (the distance =10 µm, L=7mm).  (b): Relationship between 













































































Relationship between capture efficiency and the shapes of the micropillars (the distance d 
=10 µm, flow rate=5 mL/min, L=7mm) 
Although we found the optimal design of microreactors that have a high capability 
to capture trace ketones and aldehydes in air and breath, there still exists a significant issue, 
which is that the operating time is very long. Currently, the volume of the bag we use is 1L 
and the flow rate experiment shows that high flow rate significantly decreases the capture 
efficiency of the microreactors. In order to achieve higher than 90% capture efficiency, we 
can only use a flow rate of 3.5 mL/min which means the time needed to evacuate the sample 
is about 5 hours. This is a huge drawback. So our next target is to reduce the evacuation 
time. There are two ways that we considered. One is to load more ATM into the 
microreactor, and the other is to increase the flow rate but need to get the same capture 
efficiency. For the first method, we use a 7mm length microreactor with triangle shape 
micropillars and pillar distance 10 µm. 1× 10-6 mol ATM was loaded into microreactor as 
a onetime loading, second set 1.5 × 10-6 mol ATM was loaded, third set 3× 10-6 mol ATM 
was loaded into microreactor. 5 nmol acetaldehyde, pentanal, 2-butanone and 2-pentanone 
dissolved in 5 µL methanol was injected into 1L Tedlar bag which filled with 1L pure 
Nitrogen. Different capture efficiencies were achieved under different flow rate. Figure 
2.11 shows that 4 different compounds capture efficiencies under different flow rate with 
different ATM loading. The loading change almost has no effect on capture efficiencies of 
all compounds. This is mostly because the concentration of ATM was much larger than 
that of the compounds to be captured. In this case, we need to use the second way. For the 
second way, we proposed a different design of microreactor with increasing the length of 
the microreactor, this increase the numbers of micropillars inside the microreactor and also 
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the residence time which make it possible to capture more carbonyl compounds in a short 
time. 
A designed microreactor with triangular micropillar shape and 10 μm distance 
between micropillars was fabricated.  The difference compared with the 7mm generation 
chip is that the length is double, triple, 4 times and 6 times of the first generation chip. In 
order to obtain higher capture efficiency with higher evacuation flow rate. 1.5 μmol of 
ATM was loaded into the microreactor with 14mm length, 21mm length, 28mm length and 
42mm length microreactor.  1L pure nitrogen was filled in Tedlar bags from a cylinder of 
99.99% high purity nitrogen to evacuate through the microreactor by a vacuum pump. 5μL 
mix standard solution (this 5μL solution contains 5nmol of Acetaldehyde, Acetone, 2-
butanone and Pentanal, respectively), was injected to the 1L nitrogen Tedlar bag. With the 
fabricated microreactors, we start to characterize the microreactor with different flow rates. 
Here we tested the flow rate of 3.5mL/min, 5mL/min, 7mL/min, 8mL/min, 10mL/min, 
15mL/min and 20mL/min. After the evacuation process, ATM and its adducts were eluted 
out of the microreactor with 200 µL methanol and the eluted solutions were then analyzed 







(a)                                                                       (b) 
(c)                                                                     (d) 
Figure 2.11 Relationship between capture efficiency and flow rate of the microreactors 
with cylindrical micropillars at different ATM loading; (a) Acetaldehyde, (b) pentanal, (c) 
2-butanone and (d) 2-pentanone (the distance =10 µm, L=7mm).   
Figure 2.12 shows that all the capture efficiencies decrease as the flow rate 



























































































first generation microreactors has the highest capture efficiencies compared to other design 
of microreactors at the same flow rate. When the flow rate is less than 5mL/min, the 
difference of the capture efficiencies among different length microreactors is very small 
because at low flow rate, the capture efficiency already reaches above 95%. For the 4- and 
6-times length microreactors, the capture efficiency is still above 95% even though the 
flow rate is at 10 mL/min and the difference between these two length microreactor is small. 
When the flow rate increases to higher than 10 mL/min, the capture efficiencies of all 
microreactors decrease to below 90%. Therefore, the flow rate of 10 mL/min should be the 
maximum flow rate that can be used for evacuation of exhaled breath samples. Now the 
process time will only take one-third of the original process time which is a great progress 
of this research. Previously we use the flow rate of 3.5mL/min to evacuate breath samples, 
it will take about 6 hours to finish one 1L sample. For the one length (7mm) microreactor, 
in order to achieve 95% capture efficiency, the flow rate needs to be lower than 3.5ml/min. 
For 21mm length or longer length microreactor, the flow rate can increase up to 8 ml/min 
with the same 95% capture efficiency. It is not always better to increase the length of 
microreactor, one concern is that if the microreactor is too long, it will be hard to operate 
during the process and it is not good for loading more ATM and eluting process due to 
contamination and recovery of ATM adducts. Also the cost of fabrication will increase for 
the longer microreactors. After considering the effect of operation, economic and practical 
application, we conclude that 21mm length microreactors will be the best design for breath 
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Figure 2.12 The capture efficiency with different flow rate using different length of design 
























































5. Modeling of the Microreactor 
In the previous study, we found that the different length of microreactors can 
achieve different capture efficiency under different flow rate of gaseous samples. Overall, 
the longer microreactors can achieve higher capture efficiency. So, we finally choose to 
use 21mm length microreactor for capture VOCs in order to balance the cost of wafer, 
ATM loading and the capture efficiency. In order to further understand the relationship 
between the capture efficiency and the length of the microreactors, we endeavor to 
establish a model to predict the relationship between the flow rate and the capture 
efficiencies of carbonyl compounds.  
The microreactors are microliter-sized reactors that have thousands of vertical 
micropillars which are coated with ATM on the surfaces. The air flows through the empty 
area between micropillars and ATM captures VOCs by oximation reaction during this 
process. So we simplify this microreactor as a packed bed reactor. Applying chemical 
reaction theory, we can find whether this capture process is mass transfer-limited, or 
reaction limited. 
5.1 Kinetics study of oximation reaction in microreactor 
In order to further design aminooxy salts for selective capture of some specific 
carbonyl compounds, the reaction kinetics of aminooxy salts with ketones, aldehydes were 
studied.  
The whole experiment set up is the same as previous described, 21mm length 
microreactor was used in this experiment. A constant amount of 1.5×10-6 mol ATM was 
loaded into microreactor and dried in oven. 5×10-9 to 1×10-6 mol 2-butanone, acetone, 
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acetaldehyde and pentanal dissolved in 5 µL methanol was injected into Tedlar bag which 
filled with 500 mL pure nitrogen. The flow rate of gaseous samples was adjusted to 
7mL/min by a flowmeter. Each experiment was operated under four different temperatures 
(30°C, 50°C, 70°C and 90°C). The microreactor was eluted out with 200 µL methanol for 
UHPLC-MS analysis. Different conversions were measured from difference 
concentrations of carbonyl compounds. Figure 2.13 shows that, as carbonyl concentration 
increases, the conversion also increases. The conversion of acetone was higher than those 
of 2-butanone, acetaldehyde and pentanal at the same carbonyl concentration while 2-
butanone conversion is higher than pentanal. These results also imply that the ATM 
reaction rate with low molecular weight aldehydes may be greater than that with high 
molecular weight aldehydes, same trend for ketones. These results may imply the 
difference in reaction kinetics of carbonyls with ATM. The dependence of the ATM-
carbonyl formation rate on the carbonyl concentrations is displayed in Figure 2.14. It is 
clearly visible, how the reaction rate increased with the increase of the carbonyl 
concentrations. Figure 2.14 shows that the curve of different carbonyl concentrations is 
rather linear. Thus, it reveals that the carbonyl reaction order is close to one. In order to 
figure out the exact reaction order of carbonyl reaction, the logarithm of the rate of 
formation of ATM-Carbonyls as a function of the logarithms of the carbonyl 
concentrations is plotted in Figure 2.15. It reveals the apparent reaction order for carbonyl 
is 0.9024, which is very close to the first order reaction. 
The volume of 21mm length microreactor is 0.0588mL, five different flow rates of 
3.5 mL/min, 5 mL/min, 7mL/min, 10mL/min and 15mL/min was used for evacuating all 
samples. 5×10-9 mol of 2-butanone, acetone, acetaldehyde and pentanal was injected into 
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500 mL Tedlar bags, each sample was tested under 5 different flow rate and calculate 
capture efficiency. (take 2-butanone as an example, if we consider the molecular flow 
through the microreactor during the residence time which is effective reaction time 
(t=1.008s for 3.5 mL/min flow rate), during this time, the ATM will capture some of the 
molecular and some molecular escapes from the microreactor. When the 500 mL Tedlar 
bad was fully evacuated, the capture amount of 2-butanone inside the microreactor was 
calculated, the uncaptured amount escaped from the microreactor. The uncaptured amount 
also accumulated from the time the gas flow through the microreactor. So at a very short 
time, the volume of gaseous goes from the inlet of microreactor equals to that from outlet 
port. The whole process of evacuation was accumulated by lots of residence time. So the 
natural logarithm of the ration of concentration of inlet and outlet ln 
𝐶𝑖𝑛𝑙𝑒𝑡
𝐶𝑜𝑢𝑡𝑙𝑒𝑡




 )) CE stands for capture efficiency. 
𝐴𝑇𝑀 + 2 − 𝑏𝑢𝑡𝑎𝑛𝑜𝑛𝑒 → 𝐴𝑇𝑀 − 2 − 𝑏𝑢𝑡𝑎𝑛𝑜𝑛𝑒 + 𝐻2𝑂                                      (1) 
   +     →  +  H2O 
 
Scheme 1. A Scheme of ATM reacted with 2-butanone. 
 
The reaction is first order for both ATM and carbonyl compounds. The molar 
amount of ATM in the experiments is much larger than carbonyls (at least 100:1), ATM 
concentration (amount) is considered as a constant and is included in the reaction constant 






= −𝑘𝐶2−𝑏𝑢𝑡𝑎𝑛𝑜𝑛𝑒                                                                         (2) 
𝑑𝐶2−𝑏𝑢𝑡𝑎𝑛𝑜𝑛𝑒
𝐶2−𝑏𝑢𝑡𝑎𝑛𝑜𝑛𝑒
 = -𝑘dt                                                                                           (3) 




 = 𝑘 𝑡                                                                                                (4) 
The reaction rate constant 𝑘  can be obtained by linear regression between the 
natural logarithm of the ratio of concentration of inlet and outlet ln 
𝐶𝑖𝑛𝑙𝑒𝑡
𝐶𝑜𝑢𝑡𝑙𝑒𝑡
, which can be 
calculated from the measured capture amount of compound, and the reaction time (t). 
Figure 2.16 shows the regression plots between these two with 2-butanone. 
 
 

































Figure 2.15 Determination of the reaction orders: the parity of the logarithm of the ATM-



































































(a)                                                                       (b) 
 
(c)                                                                      (d) 
Figure 2.16 Linear regression plots of lnCinlet/Coutlet vs t between ATM and 2-butanone 
reactions at (a) 30°C, (b) 50°C, (c) 70°C, (d) 90°C. 
From the regression plots, the slope the plot represents the 𝑘. 









































































































𝑅𝑇                                                                 (5) 
where k is the rate constant of the reaction, k0 is the frequency factor, Ea is the activation 
energy, T is the temperature (in kelvin), and R is the gas constant. We can obtain: 






) + 𝑙𝑛𝑘0                                                         (6) 
The activation energy and frequency factor were determined after linear regression 
between the mean of ln(k) in four different reaction time at the same temperature and 1/T.  
The reaction kinetics of acetone, 2-butanone, acetaldehyde and pentanal were 
measured using the same procedures as that of acetone. Figure 2.17 shows the linear 
regression plots of the natural logarithm of reaction constant (ln(k)) between ATM and 
carbonyl compounds vs 1/T.  
                                                                      































                                                                                                                                                                                                      
Figure 2.17 Linear regression plots of ln(k) vs 1/T between ATM and carbonyl compounds 
reactions. (a) Acetone, (b) 2-Butanone, (c) Acetaldehyde, (d) Pentanal. 
Table 2.1 shows the activation energy and frequency factor of each reaction.  
Table 2. 1 
The activation energy, frequency factor, coefficient of determination of linear regression  
and reaction constant in each reaction. 
 Ea(J/mol) K0(S
-1) R2 K(S-1) 
Acetone 315.22 3.496 0.954 3.1587 
2-Butanone 279.41 3.487 0.9771 3.0827 
Acetaldehyde 282.86 3.432 0.9657 3.1416 
Pentanal 268.29 3.231 0.932 3.0107 
 

























(c)  (d)  
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5.2 Modeling study of oximation reaction in microreactor 
We simplify the microreactor as a packed bed reactor. In many packed bed 
reactions, the overall rate of reaction is limited by the rate of mass transfer of reactants and 
products between the bulk fluid and the catalytic surface. Mass transfer usually refers to 
any process in which diffusion plays a role.  
In this section we consider two limiting cases of diffusion and reaction in the 
microreactor. In the first case the reaction is so rapid that the rate of diffusion of the reactant 
to the surface limits the reaction rate. In the second case, the reaction is so slow that 
virtually no concentration gradient exists in the gas phase. 
In our microreactor model, the carbonyl compounds reaction is fast enough than 
diffusion, we first consider this oximation reaction is mass transfer limited and we will 
discuss the details information below. Under this circumstance the specific reaction rate 
constant is much greater than the mass transfer coefficient, 𝑘𝑟»𝑘𝑐, and 
𝑘𝑐
𝑘𝑟





 = 𝑘𝑐𝐶𝐴 
 
Figure 2.18 Diffusion across stagnant film surrounding catalyst pellet. 
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The boundary condition at the external surface is 
-rA″= WAr=kc (CA-CAs)                                                                 (7) 
Where   kc = mass transfer coefficient 
  CA = bulk concentration 
CAs = concentration of A at the catalytic surface 
According to the book ‘Elements of Chemical Reaction Engineering’,95 we have, for the 
constant superficial velocity U,   -U
𝑑𝐶𝐴
𝑑𝑧
 + rA″ ac=0                                     (8) 
Substituting for rA″in above equation, we have -U
𝑑𝐶𝐴
𝑑𝑧
 - kc ac (CA-CAs) = 0    (9) 
In most mass transfer-limited reaction, the surface concentration is negligible with 
respect to the bulk concentration (CA » CAs), so -U
𝑑𝐶𝐴
𝑑𝑧
 = kc ac CA              (10) 
With the boundary condition at z=0, CA= CA0, we get 
𝐶𝐴
𝐶𝐴0
 = exp (-
𝑘𝑐𝑎𝑐𝑧
𝑈
)  (11) 
 
The concentration profile down a reactor of length L is shown in Figure 
 
Figure 2.19 Axial concentration profile in a packed bed. 
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The definition of conversion is X=
𝐶𝐴0−𝐶𝐴𝐿
𝐶𝐴0







Solve the equation, then we get X= 1- exp (-
𝑘𝑐𝑎𝑐𝐿
𝑈
)                                              (12) 
Where ac is surface area per volume of pillar. 
      Since the microreactor has thousands of micropillars inside it. We can take one 
of these pillars as a cell to study. the height of this cell is 400µm and the length of triangular 
























=0.3056                        (15) 
Where A is surface area of the pellet, dp is particle diameter and 
Ø porosity.  
     The kc, mass transfer coefficient can be calculated by the equation of textbook 








1/2                                                       (16) 
Since we use cylinder air as carrier gas, at room temperature and standard pressure, 
the ʋ which is kinematic viscosity is 14.8×10-6 m2/s. We take 7mm length microreactor as 
an example to calculate, the parameters of microreactor are 7mm length, 7mm length width 
and 400µm depth of micropillars. For the flow rate of 7mL/min, we can convert to get the 
velocity of flow is 0.417 m/s. Refer to Li L. etc paper96, the gas phase diffusivity (DAB) of 
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2-butanone is 0.8×10-6 m2/s, Acetone is 0.85×10-6 m2/s, Acetaldehyde is 0.75×10-6 m2/s 
and Pentanal is 0.78×10-6 m2/s. Then we can calculate kc for the reaction of 2-butanone 
with ATM was determined to be 0.02255 m/s and the kc for acetone, acetaldehyde and 
pentanal are 0.022817 m/s, 0.02059 m/s and 0.02013 m/s respectively. Then we plug kc 
and ac into equation (12). 
   With equation (12), when we have the microreactor length and flow rate the air 
flow through the micropillar, we can get capture efficiency of the microreactor. A plot of 
different flow rate and capture efficiency of these different design microreactors was 
showed below to describe the modeling results and the experimental results. A relatively 
high matching trend was discovered. Figure 2.20 shows the 2-butanone experimental data 
compared to model calculated data of the microreactors with 5 different lengths under 
different flow. As clearly see from the figure, the model equation described the 
experimental data almost equally except that at high flow rate (>15 ml/min), there is a 




Figure 2.20 Comparison of experimental data and the model simulation for capture 
efficiencies of 2-Butanone using five different length microreactors. 
 
Figure 2.21 shows that the 21mm length of microreactor’s experimental data 
compared with simulated data at mass transfer limiting. As can be seen from the figure, 
when the flow rate under 15 ml/min, the model shows a very fit to the experimental data. 
Only when the flow rate at 20 ml/min, there is slightly different between the model data 
and experimental data. These can be explained by the theory we discussed previously, 
when the flow rate is high enough that the diffusion between carbonyls and ATM are fast 



















































Figure 2.21 Comparison of experimental data with the model simulation for capture 
efficiencies of acetaldehyde, acetone, 2-butanone and pentanal with 21mm length 



























































When the reaction is slow and reaction rate limiting when mass transfer effects are 
not important. When the specific reaction rate is small with respect to the mass transfer 








 = 𝑘𝑟𝐶𝐴                                                   (17) 
The 𝑘  (reaction constant) already calculated from the kinetic study when the 
reaction is rate limiting, at room temperature, the 𝑘for 2-butanone is 3.0827 s-1, and the 
𝑘for acetone, acetaldehyde and pentanal are 3.1587 s-1, 3.1416 s-1and 3.0107 s-1respectively. 
In order to use model equation at reaction rate limiting, 𝑘𝑟 need to be calculated. By the 
unit calculation of equation (7) and (17) we get the 𝑘𝑟 calculated by 1000 𝑘/ac. Then the 
calculated 𝑘𝑟  of 2-butanone is 0.06946 m/s, and the 𝑘𝑟  for acetone, acetaldehyde and 
pentanal are 0.07117 s-1, 0.07079 s-1and 0.06784 s-1respectively. 
In order to further study the oximation reaction in the microreactor, we further plot 
the ATM-carbonyls formation rate with U1/2. if the ATM-carbonyls formation rate (mol/s) 
linearly to the U1/2, the reaction is mass transfer limited, otherwise, it is reaction limited. 
Figure 2.22 shows the relationship between ATM-carbonyls formation rate and U1/2 with 
7mm length microreactor and 42mm microreactor. As can clearly see from the figure, with 
7mm length microreactor, at low flow rate (smaller than 10 mL/min), the ATM-carbonyls 
formation rate is linearly to U1/2. At low velocities the mass transfer boundary layer 
thickness is large and diffusion limits the reaction. As the velocity past the micropillars is 
increased, the boundary layer thickness decreases and mass transfer across the boundary 
layer no longer limits the rate of reaction, it is reaction limited. This data also demonstrates 
that at low flow rate the reaction is mass transfer limited and when use calculated Kc for 
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model equation, it shows a good fit with experimental data. When at high flow rate it is not 











































































Figure 2.22 Relationship ATM-Carbonyls formation rate with U1/2 with 21mm and 













































6. Human Breath Analysis With Different Length Microreactors 
After the modeling, the next step is the practical application of the microreactor for 
human breath analysis. In this part, we collect 5L exhaled breath sample in one Tedlar bag 
from healthy subjects, then separate each 5L breath sample into aliquots of 500 mL breath 
samples. 7mm and 21mm length microreactors were prepared by loading 1.5×10-6 mol 
ATM and drying in oven. Then the 7mm length microreactor was evacuated under a flow 
rate of 3.5 ml/min while the 21mm length microreactors were evacuated under flow rate of 
8ml/min and 10ml/min. The calculated capture amount of 7mm length microreactor at 
3.5ml/min flow rate was set as a reference. For the captured amount of 21mm length 
microreactors was compared to the 7mm length microreactor under 3.5 ml/min flow rate. 
Figure 2.23 shows the capture amount of carbonyl VOCs in same exhaled breath in 3 
different conditions. It is clearly seen from the figure that the 21mm-length microreactor 
at a flow rate of 8 mL/min has a higher capture efficiency than that of the 7mm length 
microreactor at 3.5 mL/min for all compounds. So we conclude that a 21mm length 
microreactor can use at a flow rate of up to 8mL/min which can still have high capture 
efficiency than 7mm length microreactor. This significantly decreases the analysis time by 





Figure 2.23 Comparison of 7mm length microreactor capture and 21mm length 
microreactor. 
7. Conclusion 
The results of this work show that a microreactor can be used to capture more than 
95% carbonyl compounds in nitrogen. The microreactor is functionalized with the 
quaternary ammonium aminooxy compound ATM for oximation reactions with ketones 
and aldehydes. The advantages of thousands of micropillars in the microreactor include 
increasing the contact surface area for gaseous sample flowing through the chip and 
uniformly distribute gas flow to increase the chance of collision probability of ATM with 
ketones and aldehydes in the gas phase flowing through the microreactor. After studying 
the different design of microreactors with different length and micropillar shape, we find 
the capture efficiency of microreactor increasing with the increase of length at the same 
flow rate. When the length of the microreactor increases, the capture efficiency increases. 




































efficiency of it. But the increasing trend of capture efficiency will slow down when the 
length was increased to a certain length like 21mm, when further increase to 28mm and 
42mm, the capture efficiency is not a big difference compared to 21mm. The longer length 
microreactor are hard to operate. Therefore considering all these aspects, the microreactor 
with 21mm in length was recommended for future research of breath analysis. 
A novel microreactor with 21mm in length was designed to efficiently capture 
VOCs in human breath. With 21mm length microreactor, the flow rate can increase up to 
8 ml/min which can still achieve 90% capture efficiency. This significantly decrease the 
sample processing time compared to previous research. A theoretical model was developed 
to predict the capture efficiency of the microreactor related to the microreactor length and 
sample flow rate. The results of the model show a good prediction to the experimental data 








The analysis of volatile organic compounds (VOCs) in exhaled breath is promising 
for early detection of diseases including lung cancer and other cancers, diabetes, 
Tuberculosis, cystic fibrosis, and nephropathy.98 Early detection of lung cancer is a key for 
increasing survival rate of cancer patients.99, 100 Many studies have suggested that early 
stage cancers can be detected by molecular analysis of VOCs in exhaled breath.101-106  More 
than one thousand VOCs have been reported in human exhaled breath.107-109  In recent years, 
exhaled breath has become a highly researched sampling medium for identifying specific 
VOCs  as disease biomarkers for non-invasive diagnosis. However, due to trace 
concentrations (ppbv to pptv) of VOCs in exhaled breath, these analytes require 
preconcentration for quantitative analysis.120    
Recent review papers report that gas chromatography (GC) coupled with mass 
spectrometry (MS) is the most widely used system for analysis of VOCs in breath.111-113  
Since there are hundreds of trace VOCs in exhaled breath, a preconcentration process is 
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generally required to concentrate VOCs before they can be analyzed by GC-MS.  There are 
several methods that can be used for preconcentration.  The most common preconcentration 
methods are physical adsorption and thermal desorption using carbon-based adsorbents, 
polymer adsorbents in tube or in needle, and solid-phase microextraction (SPME).114-
120Proton transfer reaction mass spectrometry (PTR-MS) and selected ion flow tube mass 
spectrometry (SIFT-MS) are also used for breath analysis without preconcentration 
process.121-123 Other techniques including sensor array or electronic noses are also used for 
analysis of VOCs in exhaled breath.124, 125 
Although breath samples can be analyzed by many analytical instruments, 
preservation of the sample integrity during sample storage and sampling process is critical 
for reliable analysis of VOCs in breath samples.126-131 Tedlar bag is the most commonly 
accepted materials for collecting breath samples.128, 130,131  The storage of selected VOCs 
within sampling bags has been extensively studied.126-131 However, most of the previous 
work studied VOC stability by spiking selected VOCs into air and nitrogen matrices. The 
results indicate that the concentrations of VOCs in Tedlar bags decrease with time. Since 
there is no publication studying the stability of real breath VOCs in Tedlar bags, it is still 
not clear how long breath samples can be stored in Tedlar bags for standardizing breath 
sample storage. The stability of real breath VOCs adsorbed on sorbents (Tenax TA and 
carbograph) in tube samples has recently been studied.132-133,135  
The objective of this study is to investigate the stabilities of breath VOCs in Tedlar 
bags in order to identify appropriate storage time of breath samples at ambient temperature 
and cold temperature (4 oC). A subset of VOCs named carbonyl compounds in exhaled 
breath were   measured because these compounds are very reactive. Furthermore, carbonyl 
76 
 
compounds including 2-butanone, 3-hydroxy-2-butanone, hexanal, heptanal, nonanal, 
hydroxy-acetaldehyde, 4-hydroxy-2-hexenal (4-HHE) and 4-hydroxy-2-nonenal (4-HNE) 
have been reported as lung cancer biomarkers in exhaled breath.116-117, 134,136In this work, a 
silicon microreactor approach was used to capture trace carbonyl compounds in exhaled 
breath. Thousands of micropillars in the microreactors distribute gaseous breath flowing 
through the microreactors and provide surface areas for trapping target VOCs. The surfaces 
of the micropillars were functionalized by a quaternary ammonium aminooxy salt, 2-
(aminooxy)ethyl-N, N, N-trimethylammonium iodide (ATM), for chemoselective capture 
of aldehydes and ketones via oximation reaction. The ATM-carbonyl adducts were 
analyzed by a system of ultra high performance liquid chromatography-mass spectrometry 
(UHPLC-MS). 
2.  Experimental  
2.1 Materials   
All reagents and solvents, including deuterated acetone (acetone-d6) (99.9%), 
deuterated 2-butanone (2-butanone-d4) (99.9%), deuterated acetaldehyde (acetaldehyde-
d4) (99.9%), deuterated hexanal (hexanal-d6) (99.9%), deuterated 2-pentanone (2-
pentanone-d5) (99.9%), acetone (99%), 2-butanone (99%), 2-pentanone and methanol 
(99.9%), 5 Liter and 0.5 liter size Tedlar® bags were purchased from Sigma-Aldrich in St. 
Louis, MO. The aminooxy-based reactive coating, 2-(aminooxy) ethyl-N, N, N 
trimethylammonium iodide (ATM) was synthesized according to a published method.137 
2.2 Microreactors  
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The design and fabrication process of silicon microreactors follow standard MEMS 
device fabrication procedures. A detailed description of the fabrication of the microreactors 
has been published elsewhere. 139 The microreactors have been used for capturing carbonyl 
compounds in environmental air and exhaled breath.140 The microreactor consists of 
thousands of micropillars in an area of 21 mm in length and 7 mm in width. The 
micropillars are equilateral triangular prisms with the side length of 50 µm and the height 
of about 400 µm and the distance between two closest prisms are 10 µm. Figure 3.1 shows 
a picture of the silicon microreactor chip and a SEM micrograph of the micropillar array. 
The surfaces of the micropillars were functionalized with ATM by infusing a solution of 
ATM (1.5µmol in 30µL) in methanol into the microreactor through one connection port 
followed by evaporation of the solvent in a vacuum oven. Fused silica capillary tubes with 
350 µm in O.D. and 250 µm in I.D. were connected to the inlet and outlet ports of the 


















Figure 3.1 (a) Optical picture of a microreactor with an insert of a SEM micrograph of the 
triangular micropillar array at the top right corner; (b) the Schematic illustration of ATM 
coating on the micropillar and oximation of ATM to capture carbonyl compounds.  
 
2.3 Collection and analysis of exhaled breath samples    
After approval by the Internal Review Board of the institution and after having 
obtained written informed consent, exhaled breath samples were collected from 15 never 
smoking and 7 current smoking healthy subjects. The Tedlar bags were cleaned with high 
purity nitrogen and tested free of ketone and aldehyde contamination. Subjects directly 
breathed about a mixture of 5 liter tidal and alveolar breath into five-liter size Tedlar bags 
through the attached Teflon tube. A mixture of tidal and alveolar breath was collected in 
the sampling bags. The breath samples from smokers were collected about 10 minutes after 
smoking. After collection of breath samples, a number of 500 mL aliquots of the breath 
samples were immediately transferred into 500 mL-size Tedlar bags. Then, 5 nmole of 
each deuterated acetaldehyde, 2-butanone, hexanal, and 2-pentanone in 10 µL methanol 
was added to the 500 mL breath aliquots. The breath aliquots were stored either at room 




microreactors. The first 500 mL aliquot was immediately evacuated through a microreactor.  
The setup for evacuation of the breath samples to capture carbonyl VOCs includes a 
vacuum pump to pull the gaseous breath from the Tedlar bag through the microreactor.139-
140 The sample bags were connected to the inlet of the microreactors through septa and 
fused silica tube. The outlet of the microreactor was connected to a vacuum pump and the 
flow rate of breath sample through the microreactor was adjusted to 7 mL/min. During the 
evacuation process, carbonyl compounds react with the ATM coating and are trapped in 
the microreactor while the rest of the breath sample flows through the microreactor. Figure 
3.1 shows a schematic illustration of ATM coating on the surfaces of the micropillars and 
the oximation reaction between ATM and carbonyl compounds. After a breath sample was 
completely pulled through a microreactor, the microreactor chip was disconnected. Finally, 
the reacted ATM adduct and unreacted ATM were eluted from the chip with 200 µL 
methanol to afford ≥99% of recovered ATM-VOCs. An internal reference for UHPLC-
MS analysis was established by adding a solution of 5 × 10−9 mol of ATM-acetone-d6 
adduct in methanol to each eluted solution. The eluted solutions were directly analyzed by 
an ultra-high-performance liquid-chromatograph-mass spectrometry (MS) (UHPLC-MS) 
system.  
2.4 Ultra-high-performance liquid-chromatograph-mass spectrometry (UHPLC-MS)  
A Thermo Scientific ultra-high-performance liquid-chromatograph-mass 
spectrometry (MS) system equipped with an automatic sampler, a Vanquish UHPLC and 
a Q Exactive Focus Obitrap Mass Spectrometer was used for analysis. The UHPLC column 
compartment equipped with a Thermo Scientific Syncronis HILIC column (100 mm length, 
2.1 mm I.D., 1.7 µm particle size). The liquid flow rate through the column was 600 µL/min. 
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The column temperature stabilized at 30 °C with a total running time of 8 minutes.  The 
mobile phase A was ammonium formate and formic acid in methanol with a pH of 3.0 and 
the mobile phase B was acetonitrile. The flow system consisted of 95% of phase A and 5% 
of phase B. The injection volume of the sample was 10 µL.   
3.  Results and Discussion 
3.1 Stability of spiked deuterated carbonyl compounds in breath samples  
To determine both the capture efficiencies of carbonyl compounds by the 
microreactors and the stability of VOCs in exhaled breath, deuterated acetaldehyde, 2-
butanone, 2-pentanone and hexanal were spiked into the breath samples and then stored at 
4 oC in a refrigerator. The use of the microreactors with aminooxy coating for 
chemoselective capture of trace carbonyl compounds via oximation reactions has been 
established.137-138,93 Figure 3.2 shows that at time zero defined as immediately starting 
evacuation of the breath samples after spiking the deuterated carbonyl compounds above 
95% of these deuterated compounds were captured. Only less than 5% of each deuterated 
compound lost due to reaction in the bags and escape from the microreactor during about 
75 minutes of evacuation process. All of the spiked deuterated carbonyl compounds have 
above 85% recovery after stored for two hours before starting evacuation of the samples 
through the microreactors at room temperature. The recovery percentages of these 
compounds for the samples stored at cold temperature (4 oC) are slightly higher than that 
stored at room temperature. The spiked carbonyls in the breath samples decreased much 
faster in the first 5 hours than after 5 hours stored both at room temperature and at cold 
temperature. The two aldehydes and butanone decreased to about 80%, while pentanone 
decreased to below 80% after stored for 5 hours at cold temperature. The recovery 
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percentages of these deuterated compounds in breath samples of nonsmokers are slightly 
higher than that in breath samples of smokers. Furthermore, the recovery percentages of 
lighter acetaldehyde and butanone were higher than that of heavier hexanal and 2-
pentanone. This result is in good agreement with previous findings of higher molecular 
masses with higher losses for the study of the stability of spiked volatile breath constituents 









Figure 3.2 Capture efficiencies of spiked four deuterated compounds in breath samples (15 
Nonsmokers and 7 Smokers) with storage time at 4°C. The flow rate of breath sample 
through the microreactor was 7ml/min. (a) deuterated acetaldehyde and hexanal, (b) 
deuterated 2-butanone and 2-pentanone. 




In order to compare the recovery percentages of carbonyl compounds in Tedlar 
bags at different storage time and temperature, the amounts of breath carbonyl compounds 
in 500 mL aliquots of all breath samples in Tedlar bags from 15 nonsmokers were 
determined by evacuation through the microreactors and analyzed by UHPLC-MS in the 
same way. Given the less than 5% of loss of spiked deuterated carbonyl compounds in 
exhaled breath samples at time zero determined above, the measured amounts of carbonyl 
compounds at time zero were set as reference for calculation of the recovery percentages 
of the same compounds at the corresponding storage time both at room temperature and at 
cold temperature. The stability of breath samples was examined as the recovery 
percentages of each carbonyl compounds in the aliquots of the breath samples stored for 
up to 24 hours.   
Figure 3.3 shows the recovery percentages of ketones and aldehydes in exhaled 
breath samples. The recovery percentages of all carbonyl compounds show the trends of 
decreasing with storage time. The data also indicate that the samples stored at 4 oC have 
higher recovery percentages than that stored at room temperature. The decreases of the 
recovery percentages of carbonyl compounds in the first five hours are faster than that after 
the first five hours. The recovery percentages of saturated carbonyl compounds are above 
80% after storage for 5 hours at 4 oC. Hydroxyacetaldehyde degraded faster than 
acetaldehyde while 3-hydroxy-2-butanone degraded faster than 2-butanone. Unsaturated 
aldehydes including acrolein, crotonaldehyde, 4-hydroxy-hexenal and 4-hydroxy-nonenal 
decrease to about 80% in 1 hour stored at cold temperature. Given the evacuation time of 
75 minutes, the breath samples can be stored for a total of 2 hours to keep above 80% 
unsaturated aldehydes at cold temperature. The obviously lower recovery percentages of 
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unsaturated aldehydes in comparison with that of saturated hydroxy-carbonyl compounds 
indicate that higher reactivity of these compounds is a key factor of the loss. The loss from 
diffusion of the compounds through the films of the Tedlar bags is probably not important 
because the recovery percentages of smaller and more volatile compounds such as 

































































































































Figure 3.3 Relationship between the residual percentage and storage time of four typical 
carbonyl compounds under two conditions of storage: room temperature and cold 





























































acetaldehyde, (b) acetone and 2-butanone, (c) hydroxyacetaldehyde and 3-hydroxy-2-
butanone (d) acrolein and crotonaldehyde, (e) 4-HHE and 4-HNE.   
3.3 Long term stability of carbonyl compounds in exhaled breath samples of 
nonsmokers at low temperature   
Since lower temperature can keep higher recovery percentages of breath VOCs in 
Tedlar bags, long term stability of breath samples of the 15 nonsmokers was tested by 
storing breath samples in refrigerator at 4 oC. The recovery percentages of carbonyl 
compounds in breath aliquots were determined after 1, 2, 4, 7 and 14 days.  Figure 3.4 
shows a consistent trend of reduction in recovery percentages of ten breath carbonyl 
compounds. While all saturated carbonyl compounds decreased to about 60% to 70% range, 
unsaturated acrolein and crotonaldehyde decreased to about 39% and 4-HHE and 4-HNE 
decreased to 30% after 24 hours. The very low concentrations and high reactivity of 4-
HHE and 4-HNE make it difficult to detect them by other methods. The recovery 
percentages of lighter compounds are higher than that of heavier compounds. The fastest 
decrease of the recovery percentages are 4-HHE and 4-HNE. This long-term stability study 
indicates that breath samples can only be stored for a short period of time even at cold 
temperature. In order to recover at least 80% of carbonyl VOCs for quantitative analysis, 
breath samples in Tedlar bags will need to be stored at cold temperature and to be processed 



















Figure 3.4 Relationship between the recovery percentage and long term storage of 
representative carbonyl compounds under refrigerated cold temperature storage (4°C) with 
15 nonsmokers’ breath samples. 
3.4 Stability of carbonyl compounds in exhaled breath of smokers at cold temperature   
To investigate the stability of carbonyl compounds in exhaled breath of current 
















































































































breath, seven breath samples of smokers were collected and stored in a refrigerator at 4 oC 
for analysis. Figure 3.5 shows that the recovery percentages of all saturated carbonyl 
compounds in breath samples of smokers were lower than that in nonsmoker breath 
samples which is consistent with the stability of deuterated saturated carbonyl compounds 
spiked into smoking and nonsmoker breath samples described above. The recovery 
percentages of formaldehyde, acetaldehyde, acetone and 2-butanone, hydroxyacetaldehyde 
and 3-hydroxy-2-butanone in breath samples of nonsmokers are obviously higher that in 
breath samples of smokers. However, the recovery percentages of unsaturated carbonyl 
compounds in smoker’s breath samples were slightly higher than that in the breath samples 
of nonsmokers. The concentrations of some carbonyl compounds including acetaldehyde, 
formaldehyde, acetone and 2-butanone, hydroxyacetaldehyde in breath of cigarette 
smokers are much higher than that in breath of nonsmokers.135-137 The stability differences 
of carbonyl compounds in breath of smokers and nonsmokers are probably caused by 
higher concentrations of these compounds and other VOCs in breath of smokers produced 





























Figure 3.5 The relationship between the residual percentage and storage time of carbonyl 
compounds under refrigerated cold temperature storage (4°C) of 7 smokers’ and 15 
nonsmokers’ breath samples. (a)Formaldehyde and Acetaldehyde, (b)Acrolein and 
crotonaldehyde, (c)Hydroxyacetaldehyde and 3-hydroxy-2-butanone, (d)acetone and 2-
































4.  Conclusion 
The recovery percentages of carbonyl VOCs in breath samples stored at cold 
temperature (4 oC) are higher than that stored at room temperature. Breath samples are 
recommended to be stored at cold temperature and to be processed in 2 hours to recover 
above 80% of carbonyl compounds. Unsaturated aldehydes degrade much faster than 
saturated carbonyl compounds. The long term stability tests indicate that the recovery 
percentages of saturated carbonyl in breath samples stored at cold temperature can be above 
50% for two day while unsaturated aldehydes decrease to less than 40% within only one 
day. The recovery percentages of saturated carbonyl compounds in the breath samples of 

















Lung cancer (LC) is one of the most frequently diagnosed cancers in the world and 
is the leading causes of death worldwide, with more than 1 million deaths worldwide every 
year due to its late diagnosis and the ineffectiveness of treatment for locally advanced and 
metastatic disease. The fact that there are few symptoms during the early stages and those 
appearing during advanced stages may be not specific which caused the delayed diagnosis. 
All of this attracted a considerable interest in finding methods of diagnosis during the early 
stages. The World Health Organization classification recognizes 20 different types of 
malignant lung neoplasms.141,142 Non-small cell LC (NSCLC) and small-cell LC (SCLC) 
represent two major forms of LC disease. NSCLC is subdivided into three major histologic 
subtypes: adenocarcinoma, squamous-cell carcinoma, and large-cell carcinoma. It was 
reported that SCLC and squamous-cell carcinoma are most strongly linked with smoking 




The growing use of computed tomography (CT) has considerably increased the number of 
incidentally detected small lung nodules, especially after recent publications showing that 
low-dose CT for lung cancer screening in heavy former smokers and current smokers 
increase 20% of lung cancer patient survival rate. 144,145 However, CT screening of lung 
cancer is not specific which causes 94% of false positive prediction and a significant 
number of subjects with falsely positive radiological results undergo unnecessary invasive 
diagnostic approaches, including surgical resection although imaging techniques have 
increased the frequency of diagnosis.146 In practice, due to consolidated protocols, imaging 
techniques can reduce the number of false negatives while the positive predictive value 
remains. False positive subjects will undergo unnecessary invasive diagnostic 
interventions.147,148 Figure 4.1 shows a schematic diagram of the lung and its pathway to 
produce the VOCs. 
 
Figure 4.1 Schematic diagram of lung and its pathway to produce VOCs. 
About 50% of subjects undergoing CT in European trials had pulmonary nodules; 
20% of the subjects with pulmonary nodules were required specific management and 1-2% 
were invasively treated, leading to a false positive rate of 50-60%.149,150 So it has been 
suggested that diagnostic procedures, for example, CT scans, may lead to an excess risk of 
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cancer due to radiation.151 In this situation, an inexpensive and non-invasive test with good 
accuracy is required to identify high and low risk subjects.  
An emerging approach for diagnosing early lung cancer or other lung diseases relies 
on measuring volatile organic compounds (VOCs). It is well known that breath gas 
contains different volatile organic compounds, furthermore, lung cancer-related changes 
of VOCs are documented. The cancer cell formation and growth is accomplished by 
immunity system changes that can lead to emit different volatile organic compounds 
implicated the oxidative stress and peroxidation of the cell membrane species. There is a 
significant difference with the concentrations of VOCs in exhaled breath between healthy 
controls and lung cancer patients. By analysis of exhaled breath of lung cancer patients, 
researchers found that some volatile organic compounds can serve as biomarkers of lung 
cancer. 152-154 
As of now, smoking is a strong lung cancer (LC) risk factor and plays an important 
role in the carcinogenesis of cells in lung and affects the immunological activity and 
metabolic procedure.155 How smoking affects the body will be studied by detecting the 
exhaled VOCs from nonsmokers and smokers with different smoking behaviors. Recently 
a lot of researchers proved that tobacco smoking is a major risk factor for lung cancer.156,157 
Cigarette smoking is a mixture of more than 5000 chemical compounds, more than 60 are 
recognized to have a specific carcinogenic potential.158 With the number of cigarettes 
smoked per day and the years of smoking, there is a high risk to have lung disease. For 
non-smoking people, exposure to secondhand smoke also increases the risk of lung cancer.    
Most of the studies reported analyzed VOCs using gas chromatography mass 
spectrometry (GC-MS). GC-MS is a powerful system which enables analysis of VOCs 
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qualitatively and quantitatively, however, it needs a long time to analyze the sample and 
requires skilled operators. Solid phase microextraction–gas chromatography mass 
spectrometry (SPME-GCMS) analysis also has been used to identify exhaled breath 
biomarkers of lung cancer. But SPME also has some disadvantages, the surface area of 
SPME polymer extraction phase is small.  
The MEMS based microreactor has been successfully proved for capture of trace 
level carbonyl compounds with high capture efficiency. There are thousands of 
micropillars in the microreactors to distribute the gas flow. It also has a large surface area 
for capturing the target VOCs. In this chapter, we use microreactors which have been 
described before for quantitative analysis of trace carbonyls in exhaled breath.  
2. Breath Samples and Study Population 
Smoking can cause many lung diseases, for example, chronic obstructive 
pulmonary disease (COPD), emphysema and lung cancer. Tobacco smoking will have a 
large effect on exhaled breath when we analyze VOCs in it. Some other diseases such as 
asthma and heart disease can also affect the VOCs in our breath. To find the difference in 
breath samples between smoker group and non-smoker group for future identification of 
carbonyl markers of lung cancer, a total of 107 healthy subjects, 47 current smokers (CS) 
and 60 never smokers (NS) free from chronic lung disease or respiratory tract infection in 
the age from 25 to 80 were recruited to provide exhaled breath samples in this study, after 
approval by the Internal Review Board (IRB) at the university of Louisville and after 
having obtained written informed consent from the subjects.  
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2.1.Breath sampling and detection 
Each volunteer breathed normally to fill a 1L Tedlar bag by directly breathe into 
the air sampling bags through the attached Teflon tube. A mixed alveolar and tidal breath 
is collected. The Tedlar bag was directly connected to the silicon microreactor through 
deactivated silica tubes and septa as shown in Figure 4.3. Then, the vacuum pump forced 
gaseous breath in Tedlar bags flowing through the fabricated microreactor at a fixed flow 
rate of 3.5 ml/min. Figure 4.2 shows photos of a microreactor compared to a dime dollar, 
SEM picture of triangular shape micropillars and microscopy photo of a microreactor. 
Figure 4.3 shows a schematic setup for preconcentration of all carbonyl compounds in 
breath samples by the silicon microreactor. The microreactor length is 7mm. There are 
thousands of micropillars in the microreactor which were functionalized by a quaternary 
ammonium aminooxy, ATM salt for capture of all carbonyl compounds by oximation 
reactions. The unreacted ATM and reacted ATM adducts were eluted from the 
microreactor by flowing 150µL methanol from one slightly pressurized vial through the 
microreactor and then into an empty collecting sample vial. The eluted solutions were 
directly used for FT-ICR-MS analysis without any further process. A 5 µL solution 
containing 5 × 10 -9 mole of acetone-d6 completely reacted with ATM in methanol was 
added to each eluted methanol solution as an internal reference for FTICR-MS analysis in 
order to determine the concentrations of the carbonyl compounds in exhaled breath samples. 














Figure 4.2 (a) One microreactor compared with quarter coin, (b) Optical picture of 
fabricated microreactor and (c) SEM picture of micropillar arrays.  
 






The carbonyl VOC concentrations in exhaled breath sample of current smokers and 
never smokers were measured by FTICR-MS. Figure 4.4 shows an example spectrum of 
current smokers and never smokers. In order to further find out the difference between 
these two groups, a Wilcoxon test was applied. The Wilcoxon test can be used for 
comparing two related samples to assess whether their population means differ when the 
population cannot be assumed to be normally distributed (p<0.05 was regarded as 
significant).  
2.3.Breath analysis of patients recruited for CT screening of lung cancer 
After approved by the Internal Review Board at University of Louisville in 
Kentucky and after having obtained written informed consent, exhaled breath samples of 
117 patients, of them, 47 patients with pulmonary nodules, 70 without pulmonary nodules 
and 9 patients with COPD were collected and analyzed. All patients were recruited from a 
CT screening of early lung cancer program at Floyd Memorial Hospital. 107 healthy 
subjects, 47 current smokers (CS) and 60 never smokers (NS) described above were used 










Table 4. 1 
Subject information 
Subjects M/T* Age(mean±SD) Smoking History 

























Healthy controls 35/107 58.25±12.27 47 0 60 
* M/T = the ratio of male subjects to total subjects 
 
3. Results and Discussion 
3.1 Detection of carbonyl compounds in smokers and nonsmokers 
Tables 4.2-4.4 show the concentration ranges, median, mean and standard deviation 
(SD) value of compounds for both healthy never smoker and smoker control groups. After 
ANOVA test, Formaldehyde (p=0.000), Acetaldehyde (p=0.012) and Acetone (p<0.0001) 
show a significant higher concentration for smokers in comparison with nonsmokers. 
Figure 4.5 shows boxplots of concentrations of these three compounds in exhaled breath 
samples from current and never smokers. The results imply that formaldehyde, 
acetaldehyde and acetone are significantly affected by cigarette smoke, which may be 




Table 4. 2 
Concentration ranges and medians values of 60 never smokers and 47 current smokers 
(nmol/L) 

















































Table 4. 3 
Mean and SD values of 60 never smokers (NS) and 47 current smokers (CS) (nmol/L) 















































Table 4. 4 
Concentration ranges, medians and mean±SD values of 60 never smokers (NS) and 47 
current smokers (CS) (nmol/L) 
















































Figure 4.4 Typical FTICR-MS spectra of breath samples. (a) Current smoker, and (b) 
Never smoker. The peak of ATM is 2-(aminooxy)-N, N, N-trimethylethanammonium 
cations. The peak of IR is internal reference ATM-acetone-d6. All other peaks are ATM 
reacted with carbonyl VOCs. For example: ATM-C1H2O is ATM reacted with 









    
                                                                     
                                                                      (c) Acetone  
Figure 4.5 Comparisons of three compounds from never smokers (NS) group(n=60) and 
current smokers (CS) healthy control groups (n=47). (a) Formaldehyde, (b) Acetaldehyde, 
(c) Acetone. 
3.2.Detection of the carbonyl compounds in patients for CT screening of lung cancer 
Fourteen carbonyl compounds were also found in exhaled breath samples and their 












































































C6H12O, C7H14O, C8H16O, C9H18O, C10H20O, C2H4O2, C3H4O2, C4H8O2. After analysis of 
exhaled breath samples of pulmonary nodule patients groups, without pulmonary nodules 
groups and healthy controls groups, C3H6O (p=0.018), C2H4O2 (p=0.002) and C4H8O2 
(p=0.009) were found to have statistical significance between the pulmonary nodule group 
and HC group. C2H4O2 (p=0.001) and C4H8O (p=0.003) was found to have significantly 
higher concentrations in pulmonary nodule group than these without nodules. Figure 4.6 
shows boxplots of the concentrations of four compounds between pulmonary nodule group, 



































































































(a) C3H6O (b) C2H4O2 
(c) C4H8O2 (d) C4H8O 
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Figure 4.6 Comparisons of carbonyl compounds from healthy control (HC, n=107) group, 
pulmonary nodule (n=47) and without pulmonary (n=70) group. (a) C3H6O, (b) C2H4O2, 
(c) C4H8O2 and (d) C4H8O. 
 
According to the World Health Organization estimations, chronic obstructive 
disease (COPD) will become the third leading cause of death worldwide by 2030.159-161 
The types and concentrations of the detected VOCs can reflect the pathophysiological 
changes in human body and be linked to a specific disease, including COPD. Among the 
117 patients at Floyd Hospital, 9 patients were with COPD. After conducting ANOVA test 
between healthy control and COPD patients, C2H4O2 (p=0.005) and C4H8O2 (p=0.008) 
were found have significant difference. For C4H8O2 (p=0.008), there is a statistically 
significant higher concentrations for COPD patients and thus can be used to discriminate 
COPD patients from healthy controls while C2H4O2 (p=0.005) shows a significant lower 
concentration for COPD patients when compared to healthy controls. Figure 4.7 shows 
boxplots of the concentrations of the 2 compounds in exhaled breath samples from COPD 
patients, healthy controls and smoker patients without benign pulmonary nodules. The 
ANOVA test shows that there is no significant difference between smoker patients without 


















Figure 4.7 Comparisons of carbonyl compounds from healthy control (HC, n=107) group, 
COPD (n=9) group and smoker patients without benign pulmonary nodules (SWN, n=17) 
group. (a) C2H4O2, (b) C4H8O2.  
Asthma and chronic obstructive pulmonary disease (COPD) are widespread 
respiratory diseases involving airway inflammation. Asthma is a chronic inflammation of 
the airways that involves airflow obstruction and increased airway responsiveness to a 
variety of stimuli.162,163 A key feature is the inflammation in both proximal and distal lung 
airways. Although asthma affects people of all ages, it often starts in childhood. Asthma is 
a growing medical problem with its incidence increasing in recent years. Among the 117 
patients at Floyd Hospital, 8 patients were with asthma patients. By doing the ANOVA test, 
we found three compounds CH2O (p=0.003), C2H4O (p=0.000) and C4H8O2 (p=0.000) 
have significant higher concentrations than healthy control group. Therefore, CH2O, 




























































(a) C2H4O2 (b) C4H8O2 
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4.8 shows the boxplots of three compounds CH2O, C2H4O and C4H8O2 between healthy 














Figure 4.8 Comparisons of carbonyl compounds from healthy control (HC, n=107) group, 






















































































Since tobacco smoking and involuntary smoking are well documented in the 
scientific literature to cause cancer. It is also known that smoking cigarettes increases the 
amount of free radicals in human body. So, it is important for us to learn the smoking effect 
in breath. Of all the 117 subjects collected from Floyd hospital, it was separated into three 
groups: 19 never smokers, 69 former smokers and 29 current smokers. The criteria for 
former smokers is subjects without smoking for more than 2 days. The other smoker 
subjects were treated as current smokers. All patients were asked to fill in a questionnaire 
describing their current smoking status, for example, active smokers, non-smokers, passive 
smokers and the time elapsed since their last smoke. The classification to the appropriate 
group was done on the basis self-declaration of the volunteers. The exhaled breath was 
collected in 1L Tedlar bags which were cleaned by flushing with nitrogen gas. Then the 
microreactor method was used to evacuate the samples followed by a FTICR-MS analysis. 
Using ANOVA test, we found three carbonyl compounds (formaldehyde, acetaldehyde and 
acetone) were significant change among these groups. Figure 4.9 shows the boxplots of 
concentrations of the three identified compounds in exhaled breath samples from never 


























Figure 4.9 Comparisons of carbonyl compounds from never smoker patients (n=19) group, 
former smoking patients (n=69) and current smokers (n=29) groups. (a) CH2O, (b) C2H4O, 
(c) C3H6O. 
 
To further demonstrate the tobacco smoking will have a high effect on exhaled 
breath. We further separate the 29 current smokers into two subgroups. 20 subjects just 
smoked within 2 hours, 5 subjects did not smoke more than 4 hours but less than 2 days 






















































































same ANOVA test, Formaldehyde (p=0.017), Acetaldehyde (p=0.001) and Acetone 
(p=0.042) were also found to be significant higher in JS group than CS group. Figure 4.10 











Figure 4.10 Comparisons of carbonyl compounds from current smoker (CS) group without 
smoking for more than 4 hours (n=5), former smoker (FS) without smoking for more than 
2 days (n=4) and smoke within 2 hours (JS) group (n=20). (a) CH2O, (b) C2H4O, (c) C3H6O. 
























































































This study demonstrates the potential of MEMS based microreactors combined 
with FTICR-MS system to identify breath markers for the distinction of subjects with 
benign pulmonary nodules from healthy controls. Also, the patients with COPD and asthma 
from healthy controls. The significant differences in concentrations of these certain 
compounds in exhaled breath are related to metabolic differences of different types of lung 
diseases. The data analysis in this study did not require complicated biostatistics models. 
The biostatistics study in this research imply that breath test can be capable of detection of 
lung diseases.  
There are several advantages for this microreactor study. The microreactors are 
designed to have high capture efficiencies of all carbonyl compounds. The ATM reaction 
with carbonyl compounds through oximation reactions enables to analyze carbonyl 
compounds related to biochemical metabolites. There is also one limition for FTICR-MS 
which it is not able to identify untargeted components of a breath mixture, although it 
provides accurate chemical formula. The microreactor method is noninvasive and 
inexpensive. It does not require trained staff for their use and analysis. The microreactor 
system can also be loaded with other chemical or physical adsorbent to capture other VOCs 
in exhaled breath. The eluted analytes can be analyzed by gas chromatography-mass 
spectrometry or proton transfer reaction mass spectrometry to satisfy the need to explain 




 This study shows that smoking history effects on exhaled breath. The concentration 
ranges of formaldehyde, acetaldehyde and acetone for current smoking subjects are much 
higher than those who did not smoke. The increasing number of carbonyl compounds in 
the exhaled breath from smokers was caused by smoking cigarette. The study between 
current smokers and smokers who just smoked within two hours further shows that 
smoking can increase formaldehyde, acetaldehyde and acetone concentrations in exhaled 
breath. The study between healthy controls, patients with pulmonary nodules and patients 
without pulmonary nodules show that C3H6O, C2H4O2 and C4H8O2 can serve as biomarkers 
to distinguish patients with pulmonary nodules from healthy controls. C2H4O2 and C4H8O 
and serve as biomarkers for distinguish patients with pulmonary nodules from patients 
without pulmonary nodules. For COPD, we found that C2H4O2 and C4H8O2 can serve as 
biomarkers to identify them. Also, CH2O, C2H4O2 and C4H8O2 are good biomarkers that 








Lung cancer is one of the leading causes of death in the world and can be classified 
into two main types—non-small cell lung cancer (NSCLC) and small cell lung cancer 
(SCLC). Most lung cancer patients are diagnosed at an advanced stage when the symptoms 
(i.e., dyspnea, cough, fatigue, pain in thorax) appear and this often leads to poor prognosis. 
The most effective treatment for lung cancer currently is pulmonary surgical resection, 
however, the 5-year survival rate after surgical resection of stage ш patients is only 30% 
while stage Ι patients show up to 70%.164,165 Therefore, earlier detection of lung cancer is 
the key to increase patient survival rates. Various diagnosis tools for lung cancer such as 
chest x-ray, chest computed tomography (CT) scan, bronchoscopy, fluorodeoxyglucose-
positron emission tomography (FDG-PET) and lung biopsy are applied. However, the 
existing diagnostic procedures are invasive, expensive and inaccurate. Currently, low-dose 
CT screening is adopted for early detection of lung cancer but the false positive prediction 
is too high (96%). Recent years, more and more researchers proposed exhaled breath 
analysis can be used to detect lung cancer. There is strong evidence that molecular analysis 
of exhaled breath can be used to detect particulate cancers.166-168 Breath analysis represent
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a new diagnostic technique that is commonly thought without risk for the patient even if 
repeated frequently and it can provide information beyond conventional analysis of blood 
and urine. 169-171 Even patients at an intensive care unit or during surgery it can still be 
applied with. 172,173  
There are novel cancer biomarkers in exhaled breath for lung cancer patients. 
Various volatile organic compounds are contained in breath gas. Exhaled VOCs can 
originate from two main sources; exogenous volatiles that are inhaled and then exhaled and 
those endogenously produced by different biochemical processes through basic cellular 
functions.174 
Most of the studies reported analyzed VOCs using gas chromatography mass 
spectrometry (GC-MS).175-177Although GC-MS is a powerful system which enables 
analysis of VOCs qualitatively and quantitatively, it also has some disadvantages, for 
example, it is high cost, time consuming and requires skilled operators.178 Biomarkers from 
lung cancer patients are hard to define although many different VOCs are detected from 
human exhaled breath by GC-MS. In this study, we used a microreactor system for 
analyzing VOCs from exhaled breath to detect early stage lung cancer. A UHPLC-MS was 
used to analyze the breath samples. 
2. Breath Analysis of Lung Cancer Patient  
2.1. Test population 
After approval by the Internal Review Board at the University of Louisville in 
Kentucky and after having obtained written informed consent, exhaled breath samples of 
15 patients with untreated LC, 7 patients with benign pulmonary nodules (BN) and 15 
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healthy controls were collected and analyzed. All patients with pulmonary nodules were 
recruited in the James Graham Brown Cancer Center at the University of Louisville. 
Wilcoxon test was applied to identify specific VOCs as lung cancer markers from the 
clinically diagnosed lung cancer subjects in comparison with healthy controls. All subjects 
were patients with pulmonary nodules to be diagnosed at the time of collection of exhaled 
breath samples. The concentration ranges of these VOCs markers were determined for 
healthy controls, patients with cancer. Then these VOC markers were used to diagnose 
cancer for all other breath analysis results. A diagnostic conclusion was made based on the 
concentration levels of the specific VOCs. The diagnostic conclusions from breath analysis 
were late confirmed by the clinical diagnosis. The general sample information is listed in 
Table 5.1.  
Table 5. 1 
Subject information 
Subjects M/T* Age(mean±SD) Smoking History 
   Current Former Never 
Lung cancers 12/15 64.22±9.1 6 6 3 
Benign nodules 2/7 52.45±14.6 3 2 2 
Healthy controls 7/15 52.21±15.1 7 2 6 
* M/T = the ratio of male subjects to total subjects 
2.2. Breath sampling and detection 
Each volunteer breathed normally to fill two Tedlar bags, the two Tedlar bags were 
connected to a two-way switch valve. The first Tedlar bag is 600 mL and second Tedlar 
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bag is 400 mL. The 600 mL is tidal breath and 400mL is alveolar breath. 3L (21mm) length 
microreactors with triangular micropillars were used to evacuated breath samples. Figure 
5.1 shows a SEM photo of the microreactor with triangular micropillars. After collection, 
the Tedlar bags were directly connected to the silicon microreactor through deactivated 
silica tubes and septa as shown in Figure 5.2. Then, a vacuum pump was used to force 
gaseous breath in Tedlar breath flowing through the microreactor at a flow rate of 7mL/min. 
Figure 5.2 shows a schematic setup for preconcentration of all carbonyl compounds in 
breath samples by the silicon microreactor. A quaternary ammonium aminooxy compound, 
ATM salt for capture of all carbonyl compounds by oximation reactions was coated on the 
surface of thousands of micropillars in the microreactor. After evacuation, unreacted ATM 
and reacted ATM adducts were eluted from the microreactor by flowing 200 µL methanol. 
The eluted solutions were directly used for UHPLC-MS system analysis without any 
further process. To determine the concentrations of the carbonyl compounds, a 5 μL 
solution containing 5 × 10−9 mole of acetone-d6 completely reacted with ATM in methanol 
was added to each eluted methanol solution as an internal reference for UHPLC-MS 
analysis. 
One of the most important advantages of UHPLC-MS compared to FT-ICR-MS is 
that the UHPLC-MS has the ability to separate ketone and aldehyde with same molecular 
formula. Figure 5.3 shows examples of separation results of mixtures of 2-butanone and 
butanal, 2-pentanone and pentanal in the same solution. Also, another advantage is that 




Figure 5.1 A SEM picture of the triangular micropillars inside the microreactor and the 
photo of the microreactor compared to a dime dollar. 
 
 







Figure 5.3 UHPLC-MS spectrum separation of 2-butanone and butanal, pentanal and 2-
pentanone. 
3. Results and Discussion 
3.1. Detection of the markers and Statistical analysis 
The measured carbonyl VOC concentrations in exhaled breath sample of current 
smokers and never smokers from healthy controls were fist separated and analyzed. 
ANOVA test was applied to determine statistically significant differences between the 
groups. After ANOVA test, Formaldehyde (p=0.013), acetaldehyde (p=0.002) and acetone 
(p=0.036) presented significant higher concentrations for smokers in comparison with 
nonsmokers. Figure 5.6 shows boxplots of the concentrations of three compounds in 
exhaled breath samples from never smokers and current smokers.  
Furthermore, we separate the lung cancer patients into three groups: current 
smokers, previous smokers and never smokers. This statistical was designed to see whether 
there is same effect of smoking when a person has lung cancer. Also, all the data was input 
into Minitab software and conduct ANOVA test, after ANOVA test, formaldehyde, 
acetaldehyde and acetone in current smoker’s lung cancer patients group have significant 
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increase compared to lung cancer patients with previous smokers and never smokers. There 
are significant differences between the lung cancer patients with never smokers and current 
smokers (p<0.05) with the formaldehyde, acetaldehyde and acetone. Figure 5.7 shows the 
boxplots of the concentrations of three compounds in exhaled breath samples from lung 
cancer patients with never smokers, current smokers and previous smokers. 
Twenty carbonyl compounds (CH2O, C2H4O, C3H6O, C3H4O, C4H8O, C5H10O, 
C6H12O, C7H14O, C8H16O, C9H18O, C10H20O, C11H22O, C12H24O, C13H26O, C2H4O2, 
C3H4O2, C4H8O2, C5H8O, C7H11O and C12H22O) were detected in exhaled breath samples 
from lung cancer patients and healthy controls and their concentrations were determined. 
Figure 5.4 shows a typical UHPLC-MS spectrum under MS mode with lung cancer patient 
and healthy control. It can clearly see from the figure that most of the compounds detected 
in lung cancer patient are higher than that in healthy control. After AVOVA test of exhaled 
breath samples from the clinically diagnosed lung cancer subjects, C4H8O (p=0.022), 
C4H8O2 (p=0.037) and 4-HNE (p=0.016) were found to have statistical significance 
between the LC group and the HC group. Figure 5.5 shows the UHPLC-MS 
chromatographs of these three compounds in lung cancer patient and healthy control.   4-
HHE (p=0.098) and Hydroxyacetaldehyde (p=0.100) was also found have considerable 
difference between lung cancer group and healthy control group. Here our standard for 
defining the significant difference is p<0.05. However, there is no significant difference in 
concentrations of these lung cancer markers between BN patients and HC. Figure 5.8 
shows the boxplots of the eight compounds between HC group, LC group and BN group. 
The concentration of C4H8O and C4H8O2 in LC group was significantly higher than that in 
HC group while concentration of 4-HNE in LC group was significantly lower than HC 
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group. Therefore, C4H8O, C4H8O2 and 4-HNE were chosen as the biomarkers of lung 
cancer for diagnosis purpose. 4-HHE and hydroxyacetaldehye (p<0.1) also have a 
considerable difference between lung cancer and healthy control, but since our criteria here 
for ANOVA test is p<0.05. We do not choose these two compounds for lung cancer 
biomarkers. Table 5.2 shows the concentration ranges of these marker compounds in 
exhaled breath of lung cancer patients, benign nodule patients and healthy controls. Simple 
rules were made from the concentration ranges for lung cancer diagnosis: if 2 or more 
marker concentrations are in the lung cancer range (including the overlap area), the subject 
was assigned as lung cancer patient; otherwise the subject was considered as patient with 












Figure 5.4 Typical UHPLC-MS spectrum with mass mode between lung cancer patient and 
healthy control. 
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Figure 5.5 Typical UHPLC-MS chromatography between lung cancer patient and healthy 
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Figure 5.6 Comparisons of three compounds from never smokers (NS, n=6) and healthy 



































































































Figure 5.7 Comparisons of three compounds from lung cancer patients with never smokers 
(NS, n=3), current smokers (CS, n=6) and previous smokers (PS, n=6) groups. (a) 
formaldehyde, (b) acetaldehyde and (c) acetone. 





















































































A comparison of identified lung cancer marker concentration range, mean and SD for 






























































































































































































Figure 5.8 Comparisons of compounds with HC group (n=15), LC group (n=15) and BN 
group (n=7). (a) C4H8O, (b) C4H8O2, (c) 4-HNE, (d) 4-HHE, (e) C2H4O2, (f) C3H6O, (g) 










































































































(g) CH2O (h) C2H4O 
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3.2. Lung cancer type analysis 
To further determine the capability of identifying and characterizing lung cancer 
using these identified carbonyl VOC markers, the subjects were grouped into squamous 
cell NSCLS and adenocarcinoma NSCLC. After conducting ANOVA test, 4-HNE was 
found significant difference between squamous cell NSCLC and adenocarcinoma NSCLC 
(p=0.03). (As shown in Figure 5.9) 
 
Figure 5.9 Comparisons of 4-HNE with adenocarcinoma NSCLC (n=9) and squamous cell 
NSCLC (n=6).  
4. Conclusion  
This study demonstrates the potential of MEMS based microreactors combined 
with UHPLC-MS system to identify lung cancer breath markers for the distinction of 
subjects with lung cancer from subjects with healthy controls. The results show that 
UHPLC-MS has advantages of separation and sensitivity on carbonyl VOCs compared to 
FT-ICR-MS. The results also show that breath markers can discriminate between lung 


























markers in exhaled breath are related to metabolic differences of different types of lung 
cancers. This research demonstrated a fabricated silicon microreactor chip of 21mm length 
with triangular micropillars for preconcentration and analysis of carbonyls compounds in 
exhaled breath. We have found three VOCs (2-butanone, 3-hydroxy-2-butanone and 4-
HNE) to distinguish LC from patients with benign pulmonary nodules and healthy controls, 
particularly 4-HNE can also be used to distinguish squamous cell carcinoma from 
adenocarcinoma LC. The 4-HHE and Hydroxyacetaldehyde do not considered as markers 
for lung cancer here since p>0.05, but they are very promising since p<0.1.  
However, the test population in this study is relatively small, since this is an 
ongoing project, we are still collecting more patients subjects from Brown Cancer Center. 
Once we get enough subjects, for examples, different stages and types of lung cancer 
patients, benign pulmonary nodule patients and healthy controls. We will do statistical 
analysis can potentially find more biomarkers (especially for 4-HHE and 










This research demonstrated MEMS based microreactors coated with aminooxy 
compounds combined with UHPLC-MS for chemoselective capture and analysis of trace 




We have successfully designed a novel silicon-based microreactor with thousands 
of micropillars. The fabrication procedure follows the MEMS microfabrication techniques 
and fabricated at Micro/Nano Technology Center in University of Louisville. 
The silicon-based microreactor coated with the aminooxy reagent ATM as a 
derivatization reagent (coating) to capture trace level carbonyl compounds was 
comprehensively characterized. Different designs of the microreactor were generated by 
L-edit software. For example, 3 different pillar distance (10 µm, 25µm and 50 µm), four 
different micropillar shapes (cylindrical, square, triangle and diamond) and five different
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microreactor length (7mm, 14mm, 21mm, 28mm and 42mm). The study shows that when 
under the same microreactor length, the design with 10µm micropillar distance and triangle 
pillar shape has the best performance in capture trace aldehydes and ketones. The capture 
efficiency can achieve 95% at a gaseous flow rate less than 8 ml/min. 
The microreactors with different length were then intensively studied in this 
research. 7mm, 14mm, 21mm, 28mm and 42mm length microreactors were all loaded same 
amount of ATM since the loading effect study in chapter 2 shows the different amount of 
ATM has almost no effect on capture efficiencies. The experimental results show that the 
microreactor capture efficiencies of trace carbonyls decrease with the increasing of flow 
rate. For a certain flow rate range (<10ml/min), there is no significant capture efficiency 
difference between the 21mm, 28mm and 42mm microrractors. Considering the practical 
application and economical thought, 21mm length microreactor with 10µm and triangle 
shape micropillars is the optimal microreactor for capture of trace levels carbonyls in 
human exhaled breath. A theoretical model was then developed for modeling the 
microreactor gas reactions. Both mass transfer limiting aspect and reaction rate limiting 
aspect were discussed. The comparison between the experimental data and model data 
show that the model fit the reaction very well.  
This method was used for investigating the stability of human exhaled breath 
including smokers and nonsmokers. The results show that the recovery percentages of 
carbonyl VOCs in breath samples stored at cold temperature (4 oC) are higher than that 
stored at room temperature. Unsaturated aldehydes degrade much faster than saturated 
carbonyl compounds. The recovery percentages of saturated carbonyl compounds in the 
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breath samples of smokers are obviously lower than that in the breath samples of 
nonsmokers.   
This microreactor technology can be applied for analyzing any gas phase samples 
and also for environmental monitoring of volatile organic compounds whose 
concentrations are at ppb levels. 
This method was also used to identify breath markers for the distinction of subjects 
with pulmonary nodules from healthy controls and the patients with COPD and asthma 
from healthy controls for pilot lung cancer screening project. C3H6O, C2H4O2 and C4H8O2 
was found can serve as biomarkers to distinguish the patients with pulmonary nodules from 
healthy people. Smokers and nonsmokers also were found to have significant different in 
acetaldehyde, formaldehyde and acetone ranges. In the clinical study with lung cancer 
patients, we found three VOCs (2-butanone, 3-hydroxy-2butanone and 4-HNE) to 
distinguish LC from healthy controls. One VOC (4-HNE) to distinguish squamous cell 
carcinoma from adenocarcinoma LC. 
2. Future Directions 
There are several areas or directions in the near future, which we could further 
enhance the work presented in this dissertation. 
1. A study with a larger study population is necessary to validate the biomarkers of 
lung cancer patients and patients with pulmonary nodules that we found in this work. 
For examples, different stages of lung cancer patients, follow up study with lung 




2. In this study, only aminooxy salt was used as the coating materials in microreactors 
to capture specific carbonyl VOCs. Other compounds may also be used to coat on 
the micropillar to capture these compounds. Also, specific catalyst may also load 
into the surface on the micropillars or inside the microreactor to help trigger and 
accelerate the selected reaction in order to get more effective analysis, especially to 
reduce the analysis time to several minutes. 
3. The metabolism mechanism of VOCs in lung cancer patients’ breath is still not 
known in this study. One effective way is that to analyze the VOCs released by 
lung cancer cells which are cultured in clinical stations. For example, the headspace 
air in lung cancer cell line and culture solution.  
4. One limitation od this study is that an aminooxy coated microreactor can only 
identify or detect the carbonyl compounds components of analytical samples with 
accurate chemical formula, it can not identify other components of the sample like 
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